id	sid	tid	token	lemma	pos
chd-40	1	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-40	1	2	e1	e1	NOUN
chd-40	1	3	cancer	cancer	NOUN
chd-40	1	4	health	health	NOUN
chd-40	1	5	disparities	disparity	NOUN
chd-40	1	6	  	  	SPACE
chd-40	1	7	research	research	NOUN
chd-40	1	8	androgen	androgen	NOUN
chd-40	1	9	metabolism	metabolism	NOUN
chd-40	1	10	genes	gene	NOUN
chd-40	1	11	in	in	ADP
chd-40	1	12	prostate	prostate	NOUN
chd-40	1	13	cancer	cancer	NOUN
chd-40	1	14	health	health	NOUN
chd-40	1	15	disparities	disparity	NOUN
chd-40	1	16	wei	wei	PROPN
chd-40	1	17	liu1,2	liu1,2	PROPN
chd-40	1	18	,	,	PUNCT
chd-40	1	19	runhua	runhua	PROPN
chd-40	1	20	liu2,3	liu2,3	PROPN
chd-40	1	21	,	,	PUNCT
chd-40	1	22	lizhong	lizhong	ADJ
chd-40	1	23	wang2,3	wang2,3	PROPN
chd-40	1	24	*	*	PROPN
chd-40	1	25	1provincial	1provincial	NUM
chd-40	1	26	key	key	ADJ
chd-40	1	27	laboratory	laboratory	NOUN
chd-40	1	28	on	on	ADP
chd-40	1	29	molecular	molecular	ADJ
chd-40	1	30	and	and	CCONJ
chd-40	1	31	chemical	chemical	ADJ
chd-40	1	32	genetic	genetic	ADJ
chd-40	1	33	,	,	PUNCT
chd-40	1	34	the	the	DET
chd-40	1	35	second	second	ADJ
chd-40	1	36	hospital	hospital	NOUN
chd-40	1	37	of	of	ADP
chd-40	1	38	jilin	jilin	PROPN
chd-40	1	39	university	university	PROPN
chd-40	1	40	,	,	PUNCT
chd-40	1	41	changchun	changchun	PROPN
chd-40	1	42	130041	130041	NUM
chd-40	1	43	,	,	PUNCT
chd-40	1	44	pr	pr	ADP
chd-40	1	45	china	china	PROPN
chd-40	1	46	2department	2department	NUM
chd-40	1	47	of	of	ADP
chd-40	1	48	genetics	genetic	NOUN
chd-40	1	49	,	,	PUNCT
chd-40	1	50	university	university	NOUN
chd-40	1	51	of	of	ADP
chd-40	1	52	alabama	alabama	PROPN
chd-40	1	53	at	at	ADP
chd-40	1	54	birmingham	birmingham	PROPN
chd-40	1	55	,	,	PUNCT
chd-40	1	56	birmingham	birmingham	PROPN
chd-40	1	57	,	,	PUNCT
chd-40	1	58	al	al	PROPN
chd-40	1	59	35294	35294	NUM
chd-40	1	60	3comprehensive	3comprehensive	NUM
chd-40	1	61	cancer	cancer	NOUN
chd-40	1	62	center	center	NOUN
chd-40	1	63	,	,	PUNCT
chd-40	1	64	university	university	NOUN
chd-40	1	65	of	of	ADP
chd-40	1	66	alabama	alabama	PROPN
chd-40	1	67	at	at	ADP
chd-40	1	68	birmingham	birmingham	PROPN
chd-40	1	69	,	,	PUNCT
chd-40	1	70	birmingham	birmingham	PROPN
chd-40	1	71	,	,	PUNCT
chd-40	1	72	al	al	PROPN
chd-40	1	73	35294	35294	NUM
chd-40	1	74	*	*	PUNCT
chd-40	1	75	corresponding	correspond	VERB
chd-40	1	76	author	author	NOUN
chd-40	1	77	e	e	NOUN
chd-40	1	78	-	-	NOUN
chd-40	1	79	mail	mail	NOUN
chd-40	1	80	:	:	PUNCT
chd-40	1	81	lwang12@uab.edu	lwang12@uab.edu	NOUN
chd-40	1	82	abstract	abstract	ADJ
chd-40	1	83	for	for	ADP
chd-40	1	84	men	man	NOUN
chd-40	1	85	in	in	ADP
chd-40	1	86	the	the	DET
chd-40	1	87	united	united	PROPN
chd-40	1	88	states	states	PROPN
chd-40	1	89	,	,	PUNCT
chd-40	1	90	prostate	prostate	NOUN
chd-40	1	91	cancer	cancer	NOUN
chd-40	1	92	is	be	AUX
chd-40	1	93	common	common	ADJ
chd-40	1	94	,	,	PUNCT
chd-40	1	95	and	and	CCONJ
chd-40	1	96	newly	newly	ADV
chd-40	1	97	diagnosed	diagnose	VERB
chd-40	1	98	cases	case	NOUN
chd-40	1	99	of	of	ADP
chd-40	1	100	prostate	prostate	NOUN
chd-40	1	101	cancer	cancer	NOUN
chd-40	1	102	outnumber	outnumber	ADP
chd-40	1	103	those	those	PRON
chd-40	1	104	of	of	ADP
chd-40	1	105	all	all	DET
chd-40	1	106	other	other	ADJ
chd-40	1	107	cancer	cancer	NOUN
chd-40	1	108	types	type	NOUN
chd-40	1	109	.	.	PUNCT
chd-40	2	1	for	for	ADP
chd-40	2	2	prostate	prostate	NOUN
chd-40	2	3	cancer	cancer	NOUN
chd-40	2	4	,	,	PUNCT
chd-40	2	5	there	there	PRON
chd-40	2	6	are	be	VERB
chd-40	2	7	racial	racial	ADJ
chd-40	2	8	disparities	disparity	NOUN
chd-40	2	9	between	between	ADP
chd-40	2	10	caucasian	caucasian	ADJ
chd-40	2	11	americans	americans	PROPN
chd-40	2	12	and	and	CCONJ
chd-40	2	13	african	african	ADJ
chd-40	2	14	americans	americans	PROPN
chd-40	2	15	.	.	PUNCT
chd-40	3	1	androgens	androgen	NOUN
chd-40	3	2	and	and	CCONJ
chd-40	3	3	androgen	androgen	NOUN
chd-40	3	4	metabolism	metabolism	NOUN
chd-40	3	5	may	may	AUX
chd-40	3	6	be	be	AUX
chd-40	3	7	involved	involve	VERB
chd-40	3	8	in	in	ADP
chd-40	3	9	these	these	DET
chd-40	3	10	disparities	disparity	NOUN
chd-40	3	11	as	as	ADV
chd-40	3	12	well	well	ADV
chd-40	3	13	as	as	ADP
chd-40	3	14	in	in	ADP
chd-40	3	15	the	the	DET
chd-40	3	16	initiation	initiation	NOUN
chd-40	3	17	and	and	CCONJ
chd-40	3	18	progression	progression	NOUN
chd-40	3	19	of	of	ADP
chd-40	3	20	prostate	prostate	NOUN
chd-40	3	21	cancer	cancer	NOUN
chd-40	3	22	.	.	PUNCT
chd-40	4	1	here	here	ADV
chd-40	4	2	,	,	PUNCT
chd-40	4	3	we	we	PRON
chd-40	4	4	analyzed	analyze	VERB
chd-40	4	5	,	,	PUNCT
chd-40	4	6	in	in	ADP
chd-40	4	7	the	the	DET
chd-40	4	8	cancer	cancer	NOUN
chd-40	4	9	genome	genome	NOUN
chd-40	4	10	atlas	atlas	PROPN
chd-40	4	11	(	(	PUNCT
chd-40	4	12	tcga	tcga	PROPN
chd-40	4	13	)	)	PUNCT
chd-40	4	14	database	database	NOUN
chd-40	4	15	,	,	PUNCT
chd-40	4	16	the	the	DET
chd-40	4	17	mrna	mrna	PROPN
chd-40	4	18	expression	expression	NOUN
chd-40	4	19	of	of	ADP
chd-40	4	20	genes	gene	NOUN
chd-40	4	21	involved	involve	VERB
chd-40	4	22	in	in	ADP
chd-40	4	23	androgen	androgen	NOUN
chd-40	4	24	metabolism	metabolism	NOUN
chd-40	4	25	in	in	ADP
chd-40	4	26	prostate	prostate	NOUN
chd-40	4	27	cancer	cancer	NOUN
chd-40	4	28	based	base	VERB
chd-40	4	29	on	on	ADP
chd-40	4	30	the	the	DET
chd-40	4	31	patient	patient	NOUN
chd-40	4	32	’s	’s	PART
chd-40	4	33	race	race	NOUN
chd-40	4	34	.	.	PUNCT
chd-40	5	1	the	the	DET
chd-40	5	2	results	result	NOUN
chd-40	5	3	revealed	reveal	VERB
chd-40	5	4	that	that	SCONJ
chd-40	5	5	expressions	expression	NOUN
chd-40	5	6	of	of	ADP
chd-40	5	7	ugt2b15	ugt2b15	ADJ
chd-40	5	8	and	and	CCONJ
chd-40	5	9	cyp3a5	cyp3a5	NOUN
chd-40	5	10	are	be	AUX
chd-40	5	11	higher	high	ADJ
chd-40	5	12	but	but	CCONJ
chd-40	5	13	that	that	DET
chd-40	5	14	srd5a2	srd5a2	NOUN
chd-40	5	15	,	,	PUNCT
chd-40	5	16	cyp17a1	cyp17a1	NOUN
chd-40	5	17	,	,	PUNCT
chd-40	5	18	hsd3b2	hsd3b2	PROPN
chd-40	5	19	,	,	PUNCT
chd-40	5	20	and	and	CCONJ
chd-40	5	21	akr1c3	akr1c3	NOUN
chd-40	5	22	are	be	AUX
chd-40	5	23	lower	low	ADJ
chd-40	5	24	in	in	ADP
chd-40	5	25	african	african	ADJ
chd-40	5	26	american	american	ADJ
chd-40	5	27	prostate	prostate	NOUN
chd-40	5	28	cancers	cancer	NOUN
chd-40	5	29	than	than	ADP
chd-40	5	30	in	in	ADP
chd-40	5	31	those	those	PRON
chd-40	5	32	of	of	ADP
chd-40	5	33	caucasian	caucasian	ADJ
chd-40	5	34	americans	americans	PROPN
chd-40	5	35	.	.	PUNCT
chd-40	6	1	these	these	DET
chd-40	6	2	genes	gene	NOUN
chd-40	6	3	may	may	AUX
chd-40	6	4	relate	relate	VERB
chd-40	6	5	to	to	ADP
chd-40	6	6	the	the	DET
chd-40	6	7	racial	racial	ADJ
chd-40	6	8	disparities	disparity	NOUN
chd-40	6	9	associated	associate	VERB
chd-40	6	10	with	with	ADP
chd-40	6	11	prostate	prostate	NOUN
chd-40	6	12	cancer	cancer	NOUN
chd-40	6	13	.	.	PUNCT
chd-40	7	1	however	however	ADV
chd-40	7	2	,	,	PUNCT
chd-40	7	3	the	the	DET
chd-40	7	4	evidence	evidence	NOUN
chd-40	7	5	require	require	VERB
chd-40	7	6	validation	validation	NOUN
chd-40	7	7	and	and	CCONJ
chd-40	7	8	functional	functional	ADJ
chd-40	7	9	analysis	analysis	NOUN
chd-40	7	10	.	.	PUNCT
chd-40	8	1	keywords	keyword	NOUN
chd-40	8	2	:	:	PUNCT
chd-40	8	3	prostate	prostate	NOUN
chd-40	8	4	cancer	cancer	NOUN
chd-40	8	5	;	;	PUNCT
chd-40	8	6	racial	racial	ADJ
chd-40	8	7	disparity	disparity	NOUN
chd-40	8	8	;	;	PUNCT
chd-40	8	9	androgen	androgen	NOUN
chd-40	8	10	;	;	PUNCT
chd-40	8	11	metabolism	metabolism	NOUN
chd-40	8	12	;	;	PUNCT
chd-40	8	13	gene	gene	NOUN
chd-40	8	14	expression	expression	NOUN
chd-40	8	15	citation	citation	NOUN
chd-40	8	16	:	:	PUNCT
chd-40	9	1	liu	liu	PROPN
chd-40	9	2	w.	w.	PROPN
chd-40	9	3	liu	liu	PROPN
chd-40	9	4	r	r	PROPN
chd-40	9	5	,	,	PUNCT
chd-40	9	6	wang	wang	PROPN
chd-40	9	7	l	l	PROPN
chd-40	9	8	(	(	PUNCT
chd-40	9	9	2017	2017	NUM
chd-40	9	10	)	)	PUNCT
chd-40	9	11	.	.	PUNCT
chd-40	10	1	androgen	androgen	NOUN
chd-40	10	2	metabolism	metabolism	NOUN
chd-40	10	3	genes	gene	NOUN
chd-40	10	4	in	in	ADP
chd-40	10	5	prostate	prostate	NOUN
chd-40	10	6	cancer	cancer	NOUN
chd-40	10	7	health	health	NOUN
chd-40	10	8	disparities	disparity	NOUN
chd-40	10	9	cancer	cancer	NOUN
chd-40	10	10	health	health	PROPN
chd-40	10	11	disparities;1	disparities;1	PROPN
chd-40	10	12	:	:	PUNCT
chd-40	10	13	e1	e1	NOUN
chd-40	10	14	-	-	PUNCT
chd-40	10	15	e6	e6	NOUN
chd-40	10	16	.	.	PUNCT
chd-40	11	1	doi:10.9777	doi:10.9777	PROPN
chd-40	11	2	/	/	SYM
chd-40	11	3	rr.2017.10003	rr.2017.10003	NOUN
chd-40	11	4	          	          	SPACE
chd-40	11	5	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	ADP
chd-40	11	6	e2	e2	PROPN
chd-40	11	7	cancer	cancer	NOUN
chd-40	11	8	health	health	NOUN
chd-40	11	9	disparities	disparity	NOUN
chd-40	11	10	  	  	SPACE
chd-40	11	11	research	research	NOUN
chd-40	11	12	introduction	introduction	NOUN
chd-40	11	13	according	accord	VERB
chd-40	11	14	to	to	ADP
chd-40	11	15	the	the	DET
chd-40	11	16	latest	late	ADJ
chd-40	11	17	statistics	statistic	NOUN
chd-40	11	18	provided	provide	VERB
chd-40	11	19	by	by	ADP
chd-40	11	20	the	the	DET
chd-40	11	21	american	american	PROPN
chd-40	11	22	cancer	cancer	PROPN
chd-40	11	23	society	society	NOUN
chd-40	11	24	(	(	PUNCT
chd-40	11	25	acs	acs	PROPN
chd-40	11	26	)	)	PUNCT
chd-40	11	27	,	,	PUNCT
chd-40	11	28	there	there	PRON
chd-40	11	29	are	be	VERB
chd-40	11	30	161,360	161,360	NUM
chd-40	11	31	incident	incident	NOUN
chd-40	11	32	cases	case	NOUN
chd-40	11	33	newly	newly	ADV
chd-40	11	34	diagnosed	diagnose	VERB
chd-40	11	35	with	with	ADP
chd-40	11	36	prostate	prostate	NOUN
chd-40	11	37	cancer	cancer	NOUN
chd-40	11	38	,	,	PUNCT
chd-40	11	39	accounting	account	VERB
chd-40	11	40	for	for	ADP
chd-40	11	41	19	19	NUM
chd-40	11	42	%	%	NOUN
chd-40	11	43	of	of	ADP
chd-40	11	44	all	all	DET
chd-40	11	45	new	new	ADJ
chd-40	11	46	cancer	cancer	NOUN
chd-40	11	47	cases	case	NOUN
chd-40	11	48	in	in	ADP
chd-40	11	49	2017	2017	NUM
chd-40	11	50	and	and	CCONJ
chd-40	11	51	,	,	PUNCT
chd-40	11	52	for	for	ADP
chd-40	11	53	males	male	NOUN
chd-40	11	54	,	,	PUNCT
chd-40	11	55	leading	lead	VERB
chd-40	11	56	all	all	DET
chd-40	11	57	other	other	ADJ
chd-40	11	58	cancers	cancer	NOUN
chd-40	11	59	(	(	PUNCT
chd-40	11	60	siegel	siegel	NOUN
chd-40	11	61	et	et	PROPN
chd-40	11	62	al	al	PROPN
chd-40	11	63	.	.	PROPN
chd-40	11	64	,	,	PUNCT
chd-40	11	65	2017	2017	NUM
chd-40	11	66	)	)	PUNCT
chd-40	11	67	.	.	PUNCT
chd-40	12	1	the	the	DET
chd-40	12	2	incidence	incidence	NOUN
chd-40	12	3	varies	vary	VERB
chd-40	12	4	with	with	ADP
chd-40	12	5	race	race	NOUN
chd-40	12	6	.	.	PUNCT
chd-40	13	1	the	the	DET
chd-40	13	2	rate	rate	NOUN
chd-40	13	3	for	for	ADP
chd-40	13	4	african	african	ADJ
chd-40	13	5	american	american	PROPN
chd-40	13	6	(	(	PUNCT
chd-40	13	7	aa	aa	NOUN
chd-40	13	8	)	)	PUNCT
chd-40	13	9	men	man	NOUN
chd-40	13	10	is	be	AUX
chd-40	13	11	198.4/100,000	198.4/100,000	NUM
chd-40	13	12	,	,	PUNCT
chd-40	13	13	higher	high	ADJ
chd-40	13	14	than	than	ADP
chd-40	13	15	114.8/100,000	114.8/100,000	NUM
chd-40	13	16	for	for	ADP
chd-40	13	17	caucasian	caucasian	ADJ
chd-40	13	18	american	american	PROPN
chd-40	13	19	(	(	PUNCT
chd-40	13	20	ca	ca	NOUN
chd-40	13	21	)	)	PUNCT
chd-40	13	22	men	man	NOUN
chd-40	13	23	.	.	PUNCT
chd-40	14	1	although	although	SCONJ
chd-40	14	2	the	the	DET
chd-40	14	3	racial	racial	ADJ
chd-40	14	4	disparities	disparity	NOUN
chd-40	14	5	in	in	ADP
chd-40	14	6	prostate	prostate	NOUN
chd-40	14	7	cancer	cancer	NOUN
chd-40	14	8	are	be	AUX
chd-40	14	9	related	relate	VERB
chd-40	14	10	to	to	ADP
chd-40	14	11	lifestyle	lifestyle	NOUN
chd-40	14	12	,	,	PUNCT
chd-40	14	13	dietary	dietary	ADJ
chd-40	14	14	,	,	PUNCT
chd-40	14	15	socioeconomic	socioeconomic	ADJ
chd-40	14	16	,	,	PUNCT
chd-40	14	17	and	and	CCONJ
chd-40	14	18	clinical	clinical	ADJ
chd-40	14	19	factors	factor	NOUN
chd-40	14	20	,	,	PUNCT
chd-40	14	21	genetic	genetic	ADJ
chd-40	14	22	factors	factor	NOUN
chd-40	14	23	are	be	AUX
chd-40	14	24	also	also	ADV
chd-40	14	25	substantial	substantial	ADJ
chd-40	14	26	(	(	PUNCT
chd-40	14	27	chang	chang	PROPN
chd-40	14	28	et	et	PROPN
chd-40	14	29	al	al	PROPN
chd-40	14	30	.	.	PROPN
chd-40	14	31	,	,	PUNCT
chd-40	14	32	2014	2014	NUM
chd-40	14	33	;	;	PUNCT
chd-40	14	34	cooper	cooper	NOUN
chd-40	14	35	and	and	CCONJ
chd-40	14	36	page	page	NOUN
chd-40	14	37	,	,	PUNCT
chd-40	14	38	2014	2014	NUM
chd-40	14	39	;	;	PUNCT
chd-40	14	40	plata	plata	PROPN
chd-40	14	41	bello	bello	PROPN
chd-40	14	42	and	and	CCONJ
chd-40	14	43	concepcion	concepcion	PROPN
chd-40	14	44	masip	masip	PROPN
chd-40	14	45	,	,	PUNCT
chd-40	14	46	2014	2014	NUM
chd-40	14	47	;	;	PUNCT
chd-40	14	48	schaid	schaid	VERB
chd-40	14	49	,	,	PUNCT
chd-40	14	50	2004	2004	NUM
chd-40	14	51	;	;	PUNCT
chd-40	14	52	singh	singh	PROPN
chd-40	14	53	et	et	PROPN
chd-40	14	54	al	al	PROPN
chd-40	14	55	.	.	PROPN
chd-40	14	56	,	,	PUNCT
chd-40	14	57	2017	2017	NUM
chd-40	14	58	)	)	PUNCT
chd-40	14	59	.	.	PUNCT
chd-40	15	1	for	for	ADP
chd-40	15	2	most	most	ADJ
chd-40	15	3	prostate	prostate	NOUN
chd-40	15	4	cancers	cancer	NOUN
chd-40	15	5	,	,	PUNCT
chd-40	15	6	which	which	PRON
chd-40	15	7	are	be	AUX
chd-40	15	8	generally	generally	ADV
chd-40	15	9	androgen	androgen	NOUN
chd-40	15	10	-	-	PUNCT
chd-40	15	11	sensitive	sensitive	ADJ
chd-40	15	12	,	,	PUNCT
chd-40	15	13	androgen	androgen	NOUN
chd-40	15	14	withdrawal	withdrawal	NOUN
chd-40	15	15	can	can	AUX
chd-40	15	16	produce	produce	VERB
chd-40	15	17	initial	initial	ADJ
chd-40	15	18	regressions	regression	NOUN
chd-40	15	19	(	(	PUNCT
chd-40	15	20	cooper	cooper	NOUN
chd-40	15	21	and	and	CCONJ
chd-40	15	22	page	page	NOUN
chd-40	15	23	,	,	PUNCT
chd-40	15	24	2014	2014	NUM
chd-40	15	25	)	)	PUNCT
chd-40	15	26	.	.	PUNCT
chd-40	16	1	lower	low	ADJ
chd-40	16	2	levels	level	NOUN
chd-40	16	3	of	of	ADP
chd-40	16	4	intraprostatic	intraprostatic	ADJ
chd-40	16	5	androgens	androgen	NOUN
chd-40	16	6	are	be	AUX
chd-40	16	7	associated	associate	VERB
chd-40	16	8	with	with	ADP
chd-40	16	9	a	a	DET
chd-40	16	10	lower	low	ADJ
chd-40	16	11	incidence	incidence	NOUN
chd-40	16	12	of	of	ADP
chd-40	16	13	prostate	prostate	NOUN
chd-40	16	14	cancer	cancer	NOUN
chd-40	16	15	(	(	PUNCT
chd-40	16	16	cooper	cooper	NOUN
chd-40	16	17	and	and	CCONJ
chd-40	16	18	page	page	NOUN
chd-40	16	19	,	,	PUNCT
chd-40	16	20	2014	2014	NUM
chd-40	16	21	)	)	PUNCT
chd-40	16	22	.	.	PUNCT
chd-40	17	1	androgen	androgen	NOUN
chd-40	17	2	deprivation	deprivation	NOUN
chd-40	17	3	therapy	therapy	NOUN
chd-40	17	4	,	,	PUNCT
chd-40	17	5	a	a	DET
chd-40	17	6	common	common	ADJ
chd-40	17	7	treatment	treatment	NOUN
chd-40	17	8	,	,	PUNCT
chd-40	17	9	can	can	AUX
chd-40	17	10	block	block	VERB
chd-40	17	11	progression	progression	NOUN
chd-40	17	12	of	of	ADP
chd-40	17	13	metastatic	metastatic	ADJ
chd-40	17	14	prostate	prostate	NOUN
chd-40	17	15	cancer	cancer	NOUN
chd-40	17	16	(	(	PUNCT
chd-40	17	17	welsh	welsh	NOUN
chd-40	17	18	and	and	CCONJ
chd-40	17	19	hentz	hentz	ADJ
chd-40	17	20	,	,	PUNCT
chd-40	17	21	2017	2017	NUM
chd-40	17	22	;	;	PUNCT
chd-40	17	23	yang	yang	PROPN
chd-40	17	24	et	et	PROPN
chd-40	17	25	al	al	PROPN
chd-40	17	26	.	.	PROPN
chd-40	17	27	,	,	PUNCT
chd-40	17	28	2017	2017	NUM
chd-40	17	29	;	;	PUNCT
chd-40	17	30	young	young	PROPN
chd-40	17	31	et	et	PROPN
chd-40	17	32	al	al	PROPN
chd-40	17	33	.	.	PROPN
chd-40	17	34	,	,	PUNCT
chd-40	17	35	2017	2017	NUM
chd-40	17	36	)	)	PUNCT
chd-40	17	37	.	.	PUNCT
chd-40	18	1	further	far	ADV
chd-40	18	2	,	,	PUNCT
chd-40	18	3	differences	difference	NOUN
chd-40	18	4	in	in	ADP
chd-40	18	5	androgen	androgen	NOUN
chd-40	18	6	metabolism	metabolism	NOUN
chd-40	18	7	may	may	AUX
chd-40	18	8	relate	relate	VERB
chd-40	18	9	to	to	ADP
chd-40	18	10	the	the	DET
chd-40	18	11	racial	racial	ADJ
chd-40	18	12	disparities	disparity	NOUN
chd-40	18	13	in	in	ADP
chd-40	18	14	this	this	DET
chd-40	18	15	disease	disease	NOUN
chd-40	18	16	(	(	PUNCT
chd-40	18	17	singh	singh	PROPN
chd-40	18	18	et	et	PROPN
chd-40	18	19	al	al	PROPN
chd-40	18	20	.	.	PROPN
chd-40	18	21	,	,	PUNCT
chd-40	18	22	2017	2017	NUM
chd-40	18	23	)	)	PUNCT
chd-40	18	24	.	.	PUNCT
chd-40	19	1	thus	thus	ADV
chd-40	19	2	,	,	PUNCT
chd-40	19	3	for	for	ADP
chd-40	19	4	prostate	prostate	NOUN
chd-40	19	5	cancer	cancer	NOUN
chd-40	19	6	,	,	PUNCT
chd-40	19	7	androgen	androgen	NOUN
chd-40	19	8	metabolism	metabolism	NOUN
chd-40	19	9	may	may	AUX
chd-40	19	10	be	be	AUX
chd-40	19	11	involved	involve	VERB
chd-40	19	12	in	in	ADP
chd-40	19	13	racial	racial	ADJ
chd-40	19	14	disparities	disparity	NOUN
chd-40	19	15	as	as	ADV
chd-40	19	16	well	well	ADV
chd-40	19	17	as	as	ADP
chd-40	19	18	in	in	ADP
chd-40	19	19	tumor	tumor	NOUN
chd-40	19	20	imitation	imitation	NOUN
chd-40	19	21	and	and	CCONJ
chd-40	19	22	progression	progression	NOUN
chd-40	19	23	.	.	PUNCT
chd-40	20	1	for	for	ADP
chd-40	20	2	ca	ca	NOUN
chd-40	20	3	and	and	CCONJ
chd-40	20	4	aa	aa	PROPN
chd-40	20	5	men	man	NOUN
chd-40	20	6	in	in	ADP
chd-40	20	7	the	the	DET
chd-40	20	8	united	united	PROPN
chd-40	20	9	states	states	PROPN
chd-40	20	10	,	,	PUNCT
chd-40	20	11	there	there	PRON
chd-40	20	12	are	be	VERB
chd-40	20	13	differences	difference	NOUN
chd-40	20	14	in	in	ADP
chd-40	20	15	androgen	androgen	NOUN
chd-40	20	16	levels	level	NOUN
chd-40	20	17	.	.	PUNCT
chd-40	21	1	serum	serum	NOUN
chd-40	21	2	testosterone	testosterone	NOUN
chd-40	21	3	levels	level	NOUN
chd-40	21	4	of	of	ADP
chd-40	21	5	aa	aa	PROPN
chd-40	21	6	men	man	NOUN
chd-40	21	7	(	(	PUNCT
chd-40	21	8	aged	aged	ADJ
chd-40	21	9	31	31	NUM
chd-40	21	10	to	to	PART
chd-40	21	11	50	50	NUM
chd-40	21	12	)	)	PUNCT
chd-40	21	13	are	be	AUX
chd-40	21	14	about	about	ADV
chd-40	21	15	15	15	NUM
chd-40	21	16	%	%	NOUN
chd-40	21	17	higher	high	ADJ
chd-40	21	18	than	than	ADP
chd-40	21	19	those	those	PRON
chd-40	21	20	of	of	ADP
chd-40	21	21	ca	ca	NOUN
chd-40	21	22	men	man	NOUN
chd-40	21	23	(	(	PUNCT
chd-40	21	24	ellis	ellis	PROPN
chd-40	21	25	and	and	CCONJ
chd-40	21	26	nyborg	nyborg	ADJ
chd-40	21	27	,	,	PUNCT
chd-40	21	28	1992	1992	NUM
chd-40	21	29	;	;	PUNCT
chd-40	21	30	singh	singh	PROPN
chd-40	21	31	et	et	PROPN
chd-40	21	32	al	al	PROPN
chd-40	21	33	.	.	PROPN
chd-40	21	34	,	,	PUNCT
chd-40	21	35	2017	2017	NUM
chd-40	21	36	)	)	PUNCT
chd-40	21	37	.	.	PUNCT
chd-40	22	1	in	in	ADP
chd-40	22	2	prostate	prostate	NOUN
chd-40	22	3	tissues	tissue	NOUN
chd-40	22	4	of	of	ADP
chd-40	22	5	aa	aa	PROPN
chd-40	22	6	men	man	NOUN
chd-40	22	7	,	,	PUNCT
chd-40	22	8	androgens	androgen	NOUN
chd-40	22	9	,	,	PUNCT
chd-40	22	10	androstenedione	androstenedione	NOUN
chd-40	22	11	,	,	PUNCT
chd-40	22	12	and	and	CCONJ
chd-40	22	13	sex	sex	NOUN
chd-40	22	14	hormone	hormone	NOUN
chd-40	22	15	-	-	PUNCT
chd-40	22	16	binding	bind	VERB
chd-40	22	17	globulin	globulin	NOUN
chd-40	22	18	levels	level	NOUN
chd-40	22	19	are	be	AUX
chd-40	22	20	greater	great	ADJ
chd-40	22	21	than	than	ADP
chd-40	22	22	those	those	PRON
chd-40	22	23	in	in	ADP
chd-40	22	24	tissues	tissue	NOUN
chd-40	22	25	of	of	ADP
chd-40	22	26	ca	ca	NOUN
chd-40	22	27	men	man	NOUN
chd-40	22	28	(	(	PUNCT
chd-40	22	29	singh	singh	PROPN
chd-40	22	30	et	et	PROPN
chd-40	22	31	al	al	PROPN
chd-40	22	32	.	.	PROPN
chd-40	22	33	,	,	PUNCT
chd-40	22	34	2017	2017	NUM
chd-40	22	35	)	)	PUNCT
chd-40	22	36	.	.	PUNCT
chd-40	23	1	likewise	likewise	ADV
chd-40	23	2	,	,	PUNCT
chd-40	23	3	for	for	ADP
chd-40	23	4	aa	aa	PROPN
chd-40	23	5	men	man	NOUN
chd-40	23	6	,	,	PUNCT
chd-40	23	7	expression	expression	NOUN
chd-40	23	8	of	of	ADP
chd-40	23	9	the	the	DET
chd-40	23	10	androgen	androgen	NOUN
chd-40	23	11	receptor	receptor	NOUN
chd-40	23	12	(	(	PUNCT
chd-40	23	13	ar	ar	NOUN
chd-40	23	14	)	)	PUNCT
chd-40	23	15	protein	protein	NOUN
chd-40	23	16	is	be	AUX
chd-40	23	17	22	22	NUM
chd-40	23	18	%	%	NOUN
chd-40	23	19	higher	high	ADJ
chd-40	23	20	in	in	ADP
chd-40	23	21	benign	benign	ADJ
chd-40	23	22	prostate	prostate	NOUN
chd-40	23	23	tissue	tissue	NOUN
chd-40	23	24	and	and	CCONJ
chd-40	23	25	81	81	NUM
chd-40	23	26	%	%	NOUN
chd-40	23	27	higher	high	ADJ
chd-40	23	28	in	in	ADP
chd-40	23	29	prostate	prostate	NOUN
chd-40	23	30	cancer	cancer	NOUN
chd-40	23	31	tissue	tissue	NOUN
chd-40	23	32	relative	relative	ADJ
chd-40	23	33	to	to	ADP
chd-40	23	34	ca	ca	NOUN
chd-40	23	35	men	man	NOUN
chd-40	23	36	(	(	PUNCT
chd-40	23	37	gaston	gaston	PROPN
chd-40	23	38	et	et	PROPN
chd-40	23	39	al	al	PROPN
chd-40	23	40	.	.	PROPN
chd-40	23	41	,	,	PUNCT
chd-40	23	42	2003	2003	NUM
chd-40	23	43	)	)	PUNCT
chd-40	23	44	.	.	PUNCT
chd-40	24	1	these	these	DET
chd-40	24	2	differences	difference	NOUN
chd-40	24	3	may	may	AUX
chd-40	24	4	contribute	contribute	VERB
chd-40	24	5	to	to	ADP
chd-40	24	6	racial	racial	ADJ
chd-40	24	7	disparities	disparity	NOUN
chd-40	24	8	for	for	ADP
chd-40	24	9	prostate	prostate	NOUN
chd-40	24	10	cancer	cancer	NOUN
chd-40	24	11	.	.	PUNCT
chd-40	25	1	other	other	ADJ
chd-40	25	2	factors	factor	NOUN
chd-40	25	3	,	,	PUNCT
chd-40	25	4	such	such	ADJ
chd-40	25	5	as	as	ADP
chd-40	25	6	age	age	NOUN
chd-40	25	7	,	,	PUNCT
chd-40	25	8	body	body	NOUN
chd-40	25	9	mass	mass	PROPN
chd-40	25	10	index	index	NOUN
chd-40	25	11	,	,	PUNCT
chd-40	25	12	prostate	prostate	NOUN
chd-40	25	13	specific	specific	ADJ
chd-40	25	14	antigen	antigen	NOUN
chd-40	25	15	,	,	PUNCT
chd-40	25	16	and	and	CCONJ
chd-40	25	17	pathologic	pathologic	ADJ
chd-40	25	18	gleason	gleason	PROPN
chd-40	25	19	grade	grade	NOUN
chd-40	25	20	,	,	PUNCT
chd-40	25	21	may	may	AUX
chd-40	25	22	be	be	AUX
chd-40	25	23	involved	involve	VERB
chd-40	25	24	in	in	ADP
chd-40	25	25	these	these	DET
chd-40	25	26	disparities	disparity	NOUN
chd-40	25	27	(	(	PUNCT
chd-40	25	28	plata	plata	NOUN
chd-40	25	29	bello	bello	PROPN
chd-40	25	30	and	and	CCONJ
chd-40	25	31	concepcion	concepcion	PROPN
chd-40	25	32	masip	masip	PROPN
chd-40	25	33	,	,	PUNCT
chd-40	25	34	2014	2014	NUM
chd-40	25	35	;	;	PUNCT
chd-40	25	36	schaid	schaid	VERB
chd-40	25	37	,	,	PUNCT
chd-40	25	38	2004	2004	NUM
chd-40	25	39	)	)	PUNCT
chd-40	25	40	.	.	PUNCT
chd-40	26	1	however	however	ADV
chd-40	26	2	,	,	PUNCT
chd-40	26	3	whether	whether	SCONJ
chd-40	26	4	genes	gene	NOUN
chd-40	26	5	involved	involve	VERB
chd-40	26	6	in	in	ADP
chd-40	26	7	androgen	androgen	NOUN
chd-40	26	8	metabolism	metabolism	NOUN
chd-40	26	9	are	be	AUX
chd-40	26	10	primary	primary	ADJ
chd-40	26	11	factors	factor	NOUN
chd-40	26	12	for	for	ADP
chd-40	26	13	these	these	DET
chd-40	26	14	racial	racial	ADJ
chd-40	26	15	disparities	disparity	NOUN
chd-40	26	16	is	be	AUX
chd-40	26	17	not	not	PART
chd-40	26	18	known	know	VERB
chd-40	26	19	.	.	PUNCT
chd-40	27	1	therefore	therefore	ADV
chd-40	27	2	,	,	PUNCT
chd-40	27	3	with	with	ADP
chd-40	27	4	the	the	DET
chd-40	27	5	cancer	cancer	NOUN
chd-40	27	6	genome	genome	NOUN
chd-40	27	7	atlas	atlas	PROPN
chd-40	27	8	(	(	PUNCT
chd-40	27	9	tcga	tcga	PROPN
chd-40	27	10	)	)	PUNCT
chd-40	27	11	database	database	NOUN
chd-40	27	12	,	,	PUNCT
chd-40	27	13	we	we	PRON
chd-40	27	14	conducted	conduct	VERB
chd-40	27	15	an	an	DET
chd-40	27	16	expression	expression	NOUN
chd-40	27	17	analysis	analysis	NOUN
chd-40	27	18	of	of	ADP
chd-40	27	19	genes	gene	NOUN
chd-40	27	20	involved	involve	VERB
chd-40	27	21	in	in	ADP
chd-40	27	22	androgen	androgen	NOUN
chd-40	27	23	metabolism	metabolism	NOUN
chd-40	27	24	in	in	ADP
chd-40	27	25	prostate	prostate	NOUN
chd-40	27	26	cancer	cancer	NOUN
chd-40	27	27	based	base	VERB
chd-40	27	28	on	on	ADP
chd-40	27	29	the	the	DET
chd-40	27	30	patient	patient	NOUN
chd-40	27	31	’s	’s	PART
chd-40	27	32	race	race	NOUN
chd-40	27	33	.	.	PUNCT
chd-40	28	1	from	from	ADP
chd-40	28	2	the	the	DET
chd-40	28	3	findings	finding	NOUN
chd-40	28	4	,	,	PUNCT
chd-40	28	5	we	we	PRON
chd-40	28	6	have	have	AUX
chd-40	28	7	presented	present	VERB
chd-40	28	8	a	a	DET
chd-40	28	9	potential	potential	ADJ
chd-40	28	10	mechanism	mechanism	NOUN
chd-40	28	11	underlying	underlie	VERB
chd-40	28	12	androgen	androgen	NOUN
chd-40	28	13	metabolism	metabolism	NOUN
chd-40	28	14	in	in	ADP
chd-40	28	15	racial	racial	ADJ
chd-40	28	16	disparities	disparity	NOUN
chd-40	28	17	for	for	ADP
chd-40	28	18	prostate	prostate	NOUN
chd-40	28	19	cancer	cancer	NOUN
chd-40	28	20	.	.	PUNCT
chd-40	29	1	results	result	NOUN
chd-40	29	2	and	and	CCONJ
chd-40	29	3	discussion	discussion	NOUN
chd-40	29	4	we	we	PRON
chd-40	29	5	analyzed	analyze	VERB
chd-40	29	6	the	the	DET
chd-40	29	7	mrna	mrna	NOUN
chd-40	29	8	expression	expression	NOUN
chd-40	29	9	of	of	ADP
chd-40	29	10	20	20	NUM
chd-40	29	11	genes	gene	NOUN
chd-40	29	12	involved	involve	VERB
chd-40	29	13	in	in	ADP
chd-40	29	14	androgen	androgen	NOUN
chd-40	29	15	metabolism	metabolism	NOUN
chd-40	29	16	,	,	PUNCT
chd-40	29	17	including	include	VERB
chd-40	29	18	akr1c2	akr1c2	NOUN
chd-40	29	19	,	,	PUNCT
chd-40	29	20	akr1c3	akr1c3	PROPN
chd-40	29	21	,	,	PUNCT
chd-40	29	22	cyp3a4	cyp3a4	NOUN
chd-40	29	23	,	,	PUNCT
chd-40	29	24	cyp3a5	cyp3a5	NOUN
chd-40	29	25	,	,	PUNCT
chd-40	29	26	cyp7b1	cyp7b1	PROPN
chd-40	29	27	,	,	PUNCT
chd-40	29	28	cyp11a1	cyp11a1	NOUN
chd-40	29	29	,	,	PUNCT
chd-40	29	30	cyp17a1	cyp17a1	NOUN
chd-40	29	31	,	,	PUNCT
chd-40	29	32	cyp19a1	cyp19a1	PROPN
chd-40	29	33	,	,	PUNCT
chd-40	29	34	hsd3b1	hsd3b1	ADP
chd-40	29	35	,	,	PUNCT
chd-40	29	36	hsd3b2	hsd3b2	PROPN
chd-40	29	37	,	,	PUNCT
chd-40	29	38	hsd17b3	hsd17b3	PROPN
chd-40	29	39	,	,	PUNCT
chd-40	29	40	hsd17b6	hsd17b6	PROPN
chd-40	29	41	,	,	PUNCT
chd-40	29	42	hsd17b10	hsd17b10	NOUN
chd-40	29	43	,	,	PUNCT
chd-40	29	44	rdh5	rdh5	NOUN
chd-40	29	45	,	,	PUNCT
chd-40	29	46	rdh16	rdh16	PROPN
chd-40	29	47	,	,	PUNCT
chd-40	29	48	srd5a1	srd5a1	NOUN
chd-40	29	49	,	,	PUNCT
chd-40	29	50	srd5a2	srd5a2	NOUN
chd-40	29	51	,	,	PUNCT
chd-40	29	52	srd5a3	srd5a3	NOUN
chd-40	29	53	,	,	PUNCT
chd-40	29	54	ugt2b7	ugt2b7	NOUN
chd-40	29	55	,	,	PUNCT
chd-40	29	56	and	and	CCONJ
chd-40	29	57	ugt2b15	ugt2b15	ADJ
chd-40	29	58	,	,	PUNCT
chd-40	29	59	by	by	ADP
chd-40	29	60	use	use	NOUN
chd-40	29	61	of	of	ADP
chd-40	29	62	a	a	DET
chd-40	29	63	web	web	NOUN
chd-40	29	64	-	-	ADJ
chd-40	29	65	portal	portal	ADJ
chd-40	29	66	ualcan	ualcan	ADJ
chd-40	29	67	tool	tool	NOUN
chd-40	29	68	(	(	PUNCT
chd-40	29	69	chandrashekar	chandrashekar	VERB
chd-40	29	70	et	et	PROPN
chd-40	29	71	al	al	PROPN
chd-40	29	72	.	.	PROPN
chd-40	29	73	,	,	PUNCT
chd-40	29	74	2017	2017	NUM
chd-40	29	75	)	)	PUNCT
chd-40	29	76	for	for	ADP
chd-40	29	77	analyses	analysis	NOUN
chd-40	29	78	of	of	ADP
chd-40	29	79	tcga	tcga	ADJ
chd-40	29	80	gene	gene	NOUN
chd-40	29	81	expression	expression	NOUN
chd-40	29	82	data	datum	NOUN
chd-40	29	83	in	in	ADP
chd-40	29	84	52	52	NUM
chd-40	29	85	normal	normal	ADJ
chd-40	29	86	prostate	prostate	NOUN
chd-40	29	87	tissues	tissue	NOUN
chd-40	29	88	,	,	PUNCT
chd-40	29	89	147	147	NUM
chd-40	29	90	ca	ca	AUX
chd-40	29	91	prostate	prostate	NOUN
chd-40	29	92	cancer	cancer	NOUN
chd-40	29	93	tissues	tissue	NOUN
chd-40	29	94	,	,	PUNCT
chd-40	29	95	and	and	CCONJ
chd-40	29	96	6	6	NUM
chd-40	29	97	aa	aa	NOUN
chd-40	29	98	prostate	prostate	NOUN
chd-40	29	99	cancer	cancer	NOUN
chd-40	29	100	tissues	tissue	NOUN
chd-40	29	101	.	.	PUNCT
chd-40	30	1	for	for	ADP
chd-40	30	2	aa	aa	PROPN
chd-40	30	3	tissues	tissue	NOUN
chd-40	30	4	,	,	PUNCT
chd-40	30	5	there	there	PRON
chd-40	30	6	were	be	VERB
chd-40	30	7	significantly	significantly	ADV
chd-40	30	8	higher	high	ADJ
chd-40	30	9	expressions	expression	NOUN
chd-40	30	10	of	of	ADP
chd-40	30	11	5	5	NUM
chd-40	30	12	genes	gene	NOUN
chd-40	30	13	,	,	PUNCT
chd-40	30	14	including	include	VERB
chd-40	30	15	hsd3b2	hsd3b2	NOUN
chd-40	30	16	(	(	PUNCT
chd-40	30	17	cancer	cancer	NOUN
chd-40	30	18	/	/	SYM
chd-40	30	19	normal	normal	ADJ
chd-40	30	20	fold	fold	ADJ
chd-40	30	21	change	change	NOUN
chd-40	30	22	=	=	PUNCT
chd-40	30	23	1.11	1.11	NUM
chd-40	30	24	;	;	PUNCT
chd-40	30	25	p	p	X
chd-40	30	26	=	=	PUNCT
chd-40	30	27	4.31x10	4.31x10	NUM
chd-40	30	28	-	-	SYM
chd-40	30	29	2	2	NUM
chd-40	30	30	)	)	PUNCT
chd-40	30	31	,	,	PUNCT
chd-40	30	32	hsd17b3	hsd17b3	PROPN
chd-40	30	33	(	(	PUNCT
chd-40	30	34	fold	fold	VERB
chd-40	30	35	change	change	NOUN
chd-40	30	36	=	=	NOUN
chd-40	30	37	3.22	3.22	NUM
chd-40	30	38	;	;	PUNCT
chd-40	30	39	p	p	PROPN
chd-40	30	40	=	=	SYM
chd-40	30	41	1.11x10	1.11x10	NUM
chd-40	30	42	-	-	SYM
chd-40	30	43	16	16	NUM
chd-40	30	44	)	)	PUNCT
chd-40	30	45	,	,	PUNCT
chd-40	30	46	hsd17b10	hsd17b10	X
chd-40	30	47	(	(	PUNCT
chd-40	30	48	fold	fold	VERB
chd-40	30	49	change	change	NOUN
chd-40	30	50	=	=	PUNCT
chd-40	30	51	1.27	1.27	NUM
chd-40	30	52	;	;	PUNCT
chd-40	30	53	p	p	X
chd-40	30	54	=	=	PUNCT
chd-40	30	55	1.79x10	1.79x10	NUM
chd-40	30	56	-	-	SYM
chd-40	30	57	12	12	NUM
chd-40	30	58	)	)	PUNCT
chd-40	30	59	,	,	PUNCT
chd-40	30	60	srd5a1	srd5a1	NOUN
chd-40	30	61	(	(	PUNCT
chd-40	30	62	fold	fold	VERB
chd-40	30	63	change	change	NOUN
chd-40	30	64	=	=	PUNCT
chd-40	30	65	1.27	1.27	NUM
chd-40	30	66	;	;	PUNCT
chd-40	30	67	p	p	X
chd-40	30	68	=	=	SYM
chd-40	30	69	4.02x10	4.02x10	NUM
chd-40	30	70	-	-	SYM
chd-40	30	71	5	5	NUM
chd-40	30	72	)	)	PUNCT
chd-40	30	73	,	,	PUNCT
chd-40	30	74	and	and	CCONJ
chd-40	30	75	srd5a3	srd5a3	NOUN
chd-40	30	76	(	(	PUNCT
chd-40	30	77	fold	fold	VERB
chd-40	30	78	change	change	NOUN
chd-40	30	79	=	=	SYM
chd-40	30	80	1.14	1.14	NUM
chd-40	30	81	;	;	PUNCT
chd-40	30	82	p	p	X
chd-40	30	83	=	=	SYM
chd-40	30	84	2.58x10	2.58x10	NUM
chd-40	30	85	-	-	SYM
chd-40	30	86	3	3	NUM
chd-40	30	87	)	)	PUNCT
chd-40	30	88	,	,	PUNCT
chd-40	30	89	but	but	CCONJ
chd-40	30	90	significantly	significantly	ADV
chd-40	30	91	lower	low	ADJ
chd-40	30	92	expressions	expression	NOUN
chd-40	30	93	of	of	ADP
chd-40	30	94	9	9	NUM
chd-40	30	95	genes	gene	NOUN
chd-40	30	96	,	,	PUNCT
chd-40	30	97	including	include	VERB
chd-40	30	98	akr1c2	akr1c2	NOUN
chd-40	30	99	(	(	PUNCT
chd-40	30	100	fold	fold	NOUN
chd-40	30	101	change	change	NOUN
chd-40	30	102	=	=	PUNCT
chd-40	30	103	0.32	0.32	NUM
chd-40	30	104	;	;	PUNCT
chd-40	30	105	p	p	X
chd-40	30	106	=	=	PROPN
chd-40	30	107	9.42x10	9.42x10	NUM
chd-40	30	108	-	-	SYM
chd-40	30	109	3	3	NUM
chd-40	30	110	)	)	PUNCT
chd-40	30	111	,	,	PUNCT
chd-40	30	112	cyp3a5	cyp3a5	NOUN
chd-40	30	113	(	(	PUNCT
chd-40	30	114	fold	fold	NOUN
chd-40	30	115	change	change	NOUN
chd-40	30	116	=	=	NOUN
chd-40	30	117	0.14	0.14	NUM
chd-40	30	118	;	;	PUNCT
chd-40	30	119	p	p	X
chd-40	30	120	=	=	PROPN
chd-40	30	121	1.32x10	1.32x10	NUM
chd-40	30	122	-	-	SYM
chd-40	30	123	3	3	NUM
chd-40	30	124	)	)	PUNCT
chd-40	30	125	,	,	PUNCT
chd-40	30	126	cyp11a1	cyp11a1	NOUN
chd-40	30	127	(	(	PUNCT
chd-40	30	128	fold	fold	VERB
chd-40	30	129	change	change	NOUN
chd-40	30	130	=	=	NOUN
chd-40	30	131	0.21	0.21	NUM
chd-40	30	132	;	;	PUNCT
chd-40	30	133	p	p	X
chd-40	30	134	=	=	PROPN
chd-40	30	135	3.85x10	3.85x10	NUM
chd-40	30	136	-	-	PUNCT
chd-40	30	137	8)	8)	NUM
chd-40	30	138	,	,	PUNCT
chd-40	30	139	cyp19a1	cyp19a1	NOUN
chd-40	30	140	(	(	PUNCT
chd-40	30	141	fold	fold	NOUN
chd-40	30	142	change	change	NOUN
chd-40	30	143	=	=	NOUN
chd-40	30	144	0.27	0.27	NUM
chd-40	30	145	;	;	PUNCT
chd-40	30	146	p	p	X
chd-40	30	147	=	=	SYM
chd-40	30	148	4.32x10	4.32x10	NUM
chd-40	30	149	-	-	SYM
chd-40	30	150	2	2	NUM
chd-40	30	151	)	)	PUNCT
chd-40	30	152	,	,	PUNCT
chd-40	30	153	cyp7b1	cyp7b1	PROPN
chd-40	30	154	(	(	PUNCT
chd-40	30	155	fold	fold	VERB
chd-40	30	156	change	change	NOUN
chd-40	30	157	=	=	NOUN
chd-40	30	158	0.52	0.52	NUM
chd-40	30	159	;	;	PUNCT
chd-40	30	160	p	p	X
chd-40	30	161	=	=	PROPN
chd-40	30	162	2.20x10	2.20x10	NUM
chd-40	30	163	-	-	SYM
chd-40	30	164	4	4	NUM
chd-40	30	165	)	)	PUNCT
chd-40	30	166	,	,	PUNCT
chd-40	30	167	hsd17b6	hsd17b6	PROPN
chd-40	30	168	(	(	PUNCT
chd-40	30	169	fold	fold	VERB
chd-40	30	170	change	change	NOUN
chd-40	30	171	=	=	PUNCT
chd-40	30	172	0.59	0.59	NUM
chd-40	30	173	;	;	PUNCT
chd-40	30	174	p	p	X
chd-40	30	175	=	=	PROPN
chd-40	30	176	6.56x10	6.56x10	NUM
chd-40	30	177	-	-	SYM
chd-40	30	178	4	4	NUM
chd-40	30	179	)	)	PUNCT
chd-40	30	180	,	,	PUNCT
chd-40	30	181	rdh5	rdh5	NOUN
chd-40	30	182	(	(	PUNCT
chd-40	30	183	fold	fold	NOUN
chd-40	30	184	change	change	NOUN
chd-40	30	185	=	=	NOUN
chd-40	30	186	0.50	0.50	NUM
chd-40	30	187	;	;	PUNCT
chd-40	30	188	p	p	PROPN
chd-40	30	189	=	=	PROPN
chd-40	30	190	5.76x105	5.76x105	NUM
chd-40	30	191	)	)	PUNCT
chd-40	30	192	,	,	PUNCT
chd-40	30	193	srd5a2	srd5a2	NOUN
chd-40	30	194	(	(	PUNCT
chd-40	30	195	fold	fold	VERB
chd-40	30	196	change	change	NOUN
chd-40	30	197	=	=	NOUN
chd-40	30	198	0.23	0.23	NUM
chd-40	30	199	;	;	PUNCT
chd-40	30	200	p	p	NOUN
chd-40	30	201	=	=	SYM
chd-40	30	202	5.73x10	5.73x10	NUM
chd-40	30	203	-	-	SYM
chd-40	30	204	10	10	NUM
chd-40	30	205	)	)	PUNCT
chd-40	30	206	,	,	PUNCT
chd-40	30	207	and	and	CCONJ
chd-40	30	208	ugt2b7	ugt2b7	NOUN
chd-40	30	209	(	(	PUNCT
chd-40	30	210	fold	fold	NOUN
chd-40	30	211	change	change	NOUN
chd-40	30	212	=	=	PUNCT
chd-40	30	213	0.00	0.00	NUM
chd-40	30	214	;	;	PUNCT
chd-40	30	215	p	p	X
chd-40	30	216	=	=	NOUN
chd-40	30	217	1.83x10	1.83x10	NUM
chd-40	30	218	-	-	SYM
chd-40	30	219	2	2	NUM
chd-40	30	220	)	)	PUNCT
chd-40	30	221	.	.	PUNCT
chd-40	31	1	of	of	ADP
chd-40	31	2	note	note	NOUN
chd-40	31	3	,	,	PUNCT
chd-40	31	4	expressions	expression	NOUN
chd-40	31	5	of	of	ADP
chd-40	31	6	akr1c3	akr1c3	PROPN
chd-40	31	7	,	,	PUNCT
chd-40	31	8	cyp3a5	cyp3a5	NOUN
chd-40	31	9	,	,	PUNCT
chd-40	31	10	cyp17a1	cyp17a1	NOUN
chd-40	31	11	,	,	PUNCT
chd-40	31	12	          	          	SPACE
chd-40	31	13	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-40	31	14	e3	e3	NOUN
chd-40	31	15	cancer	cancer	NOUN
chd-40	31	16	health	health	NOUN
chd-40	31	17	disparities	disparity	NOUN
chd-40	31	18	  	  	SPACE
chd-40	31	19	research	research	NOUN
chd-40	31	20	hsd3b2	hsd3b2	NOUN
chd-40	31	21	,	,	PUNCT
chd-40	31	22	srd5a2	srd5a2	NOUN
chd-40	31	23	,	,	PUNCT
chd-40	31	24	and	and	CCONJ
chd-40	31	25	ugt2b15	ugt2b15	ADV
chd-40	31	26	showed	show	VERB
chd-40	31	27	significant	significant	ADJ
chd-40	31	28	differences	difference	NOUN
chd-40	31	29	in	in	ADP
chd-40	31	30	prostate	prostate	NOUN
chd-40	31	31	cancer	cancer	NOUN
chd-40	31	32	tissues	tissue	NOUN
chd-40	31	33	between	between	ADP
chd-40	31	34	ca	ca	NOUN
chd-40	31	35	men	man	NOUN
chd-40	31	36	and	and	CCONJ
chd-40	31	37	aa	aa	PROPN
chd-40	31	38	men	man	NOUN
chd-40	31	39	(	(	PUNCT
chd-40	31	40	figure	figure	NOUN
chd-40	31	41	1	1	NUM
chd-40	31	42	)	)	PUNCT
chd-40	31	43	.	.	PUNCT
chd-40	32	1	expressions	expression	NOUN
chd-40	32	2	of	of	ADP
chd-40	32	3	cyp3a5	cyp3a5	NOUN
chd-40	32	4	(	(	PUNCT
chd-40	32	5	fold	fold	NOUN
chd-40	32	6	change	change	NOUN
chd-40	32	7	=	=	NOUN
chd-40	32	8	1.38	1.38	NUM
chd-40	32	9	;	;	PUNCT
chd-40	32	10	p	p	X
chd-40	32	11	=	=	SYM
chd-40	32	12	4.32x10	4.32x10	NUM
chd-40	32	13	-	-	SYM
chd-40	32	14	2	2	NUM
chd-40	32	15	)	)	PUNCT
chd-40	32	16	and	and	CCONJ
chd-40	32	17	ugt2b15	ugt2b15	ADV
chd-40	32	18	(	(	PUNCT
chd-40	32	19	fold	fold	VERB
chd-40	32	20	change	change	NOUN
chd-40	32	21	=	=	SYM
chd-40	32	22	1.87	1.87	NUM
chd-40	32	23	;	;	PUNCT
chd-40	32	24	p	p	X
chd-40	32	25	=	=	SYM
chd-40	32	26	4.32x10	4.32x10	NUM
chd-40	32	27	-	-	SYM
chd-40	32	28	2	2	NUM
chd-40	32	29	)	)	PUNCT
chd-40	32	30	in	in	ADP
chd-40	32	31	aa	aa	NOUN
chd-40	32	32	prostate	prostate	NOUN
chd-40	32	33	cancers	cancer	NOUN
chd-40	32	34	were	be	AUX
chd-40	32	35	higher	high	ADJ
chd-40	32	36	than	than	ADP
chd-40	32	37	those	those	PRON
chd-40	32	38	for	for	ADP
chd-40	32	39	ca	ca	NOUN
chd-40	32	40	prostate	prostate	NOUN
chd-40	32	41	cancers	cancer	NOUN
chd-40	32	42	,	,	PUNCT
chd-40	32	43	but	but	CCONJ
chd-40	32	44	expressions	expression	NOUN
chd-40	32	45	of	of	ADP
chd-40	32	46	akr1c3	akr1c3	PROPN
chd-40	32	47	(	(	PUNCT
chd-40	32	48	fold	fold	ADJ
chd-40	32	49	change	change	NOUN
chd-40	32	50	=	=	SYM
chd-40	32	51	0.58	0.58	NUM
chd-40	32	52	;	;	PUNCT
chd-40	32	53	p	p	X
chd-40	32	54	=	=	SYM
chd-40	32	55	4.32x10	4.32x10	NUM
chd-40	32	56	-	-	SYM
chd-40	32	57	2	2	NUM
chd-40	32	58	)	)	PUNCT
chd-40	32	59	,	,	PUNCT
chd-40	32	60	cyp17a1	cyp17a1	NOUN
chd-40	32	61	(	(	PUNCT
chd-40	32	62	fold	fold	VERB
chd-40	32	63	change	change	NOUN
chd-40	32	64	=	=	NOUN
chd-40	32	65	0.50	0.50	NUM
chd-40	32	66	;	;	PUNCT
chd-40	32	67	p	p	X
chd-40	32	68	=	=	SYM
chd-40	32	69	4.32x10	4.32x10	NUM
chd-40	32	70	-	-	SYM
chd-40	32	71	2	2	NUM
chd-40	32	72	)	)	PUNCT
chd-40	32	73	,	,	PUNCT
chd-40	32	74	hsd3b2	hsd3b2	PROPN
chd-40	32	75	(	(	PUNCT
chd-40	32	76	fold	fold	VERB
chd-40	32	77	change	change	NOUN
chd-40	32	78	=	=	NOUN
chd-40	32	79	0.77	0.77	NUM
chd-40	32	80	;	;	PUNCT
chd-40	32	81	p	p	X
chd-40	32	82	=	=	SYM
chd-40	32	83	4.32x10	4.32x10	NUM
chd-40	32	84	-	-	SYM
chd-40	32	85	2	2	NUM
chd-40	32	86	)	)	PUNCT
chd-40	32	87	,	,	PUNCT
chd-40	32	88	and	and	CCONJ
chd-40	32	89	srd5a2	srd5a2	VERB
chd-40	32	90	(	(	PUNCT
chd-40	32	91	fold	fold	VERB
chd-40	32	92	change	change	NOUN
chd-40	32	93	=	=	NOUN
chd-40	32	94	0.71	0.71	NUM
chd-40	32	95	;	;	PUNCT
chd-40	32	96	p	p	X
chd-40	32	97	=	=	SYM
chd-40	32	98	4.32x10	4.32x10	NUM
chd-40	32	99	-	-	SYM
chd-40	32	100	2	2	NUM
chd-40	32	101	)	)	PUNCT
chd-40	32	102	were	be	AUX
chd-40	32	103	lower	low	ADJ
chd-40	32	104	in	in	ADP
chd-40	32	105	aa	aa	NOUN
chd-40	32	106	prostate	prostate	NOUN
chd-40	32	107	cancers	cancer	NOUN
chd-40	32	108	than	than	ADP
chd-40	32	109	in	in	ADP
chd-40	32	110	ca	ca	NOUN
chd-40	32	111	prostate	prostate	NOUN
chd-40	32	112	cancers	cancer	NOUN
chd-40	32	113	(	(	PUNCT
chd-40	32	114	figure	figure	NOUN
chd-40	32	115	1	1	NUM
chd-40	32	116	)	)	PUNCT
chd-40	32	117	.	.	PUNCT
chd-40	33	1	figure	figure	NOUN
chd-40	33	2	1	1	NUM
chd-40	33	3	.	.	PUNCT
chd-40	34	1	mrna	mrna	PROPN
chd-40	34	2	expression	expression	NOUN
chd-40	34	3	of	of	ADP
chd-40	34	4	genes	gene	NOUN
chd-40	34	5	involved	involve	VERB
chd-40	34	6	in	in	ADP
chd-40	34	7	androgen	androgen	NOUN
chd-40	34	8	metabolism	metabolism	NOUN
chd-40	34	9	in	in	ADP
chd-40	34	10	normal	normal	ADJ
chd-40	34	11	prostate	prostate	NOUN
chd-40	34	12	tissues	tissue	NOUN
chd-40	34	13	and	and	CCONJ
chd-40	34	14	prostate	prostate	NOUN
chd-40	34	15	cancers	cancer	NOUN
chd-40	34	16	based	base	VERB
chd-40	34	17	on	on	ADP
chd-40	34	18	the	the	DET
chd-40	34	19	race	race	NOUN
chd-40	34	20	of	of	ADP
chd-40	34	21	patients	patient	NOUN
chd-40	34	22	as	as	SCONJ
chd-40	34	23	determined	determine	VERB
chd-40	34	24	with	with	ADP
chd-40	34	25	the	the	DET
chd-40	34	26	tcga	tcga	PROPN
chd-40	34	27	database	database	NOUN
chd-40	34	28	.	.	PUNCT
chd-40	35	1	ca	ca	PROPN
chd-40	35	2	,	,	PUNCT
chd-40	35	3	caucasian	caucasian	PROPN
chd-40	35	4	american	american	PROPN
chd-40	35	5	;	;	PUNCT
chd-40	35	6	aa	aa	PROPN
chd-40	35	7	,	,	PUNCT
chd-40	35	8	african	african	PROPN
chd-40	35	9	american	american	PROPN
chd-40	35	10	.	.	PUNCT
chd-40	36	1	akr1c3	akr1c3	PROPN
chd-40	36	2	is	be	AUX
chd-40	36	3	associated	associate	VERB
chd-40	36	4	with	with	ADP
chd-40	36	5	a	a	DET
chd-40	36	6	reduction	reduction	NOUN
chd-40	36	7	of	of	ADP
chd-40	36	8	androstenedione	androstenedione	NOUN
chd-40	36	9	and	and	CCONJ
chd-40	36	10	lower	low	ADJ
chd-40	36	11	(	(	PUNCT
chd-40	36	12	mostaghel	mostaghel	NOUN
chd-40	36	13	and	and	CCONJ
chd-40	36	14	nelson	nelson	PROPN
chd-40	36	15	,	,	PUNCT
chd-40	36	16	2008	2008	NUM
chd-40	36	17	)	)	PUNCT
chd-40	36	18	production	production	NOUN
chd-40	36	19	of	of	ADP
chd-40	36	20	testosterone	testosterone	NOUN
chd-40	36	21	and	and	CCONJ
chd-40	36	22	dihydrotestosterone	dihydrotestosterone	NOUN
chd-40	36	23	(	(	PUNCT
chd-40	36	24	dht	dht	NOUN
chd-40	36	25	)	)	PUNCT
chd-40	36	26	(	(	PUNCT
chd-40	36	27	yepuru	yepuru	NOUN
chd-40	36	28	et	et	NOUN
chd-40	36	29	al	al	PROPN
chd-40	36	30	.	.	PROPN
chd-40	36	31	,	,	PUNCT
chd-40	36	32	2013	2013	NUM
chd-40	36	33	)	)	PUNCT
chd-40	36	34	.	.	PUNCT
chd-40	37	1	higher	high	ADJ
chd-40	37	2	expression	expression	NOUN
chd-40	37	3	of	of	ADP
chd-40	37	4	akr1c3	akr1c3	PROPN
chd-40	37	5	enhances	enhance	NOUN
chd-40	37	6	survival	survival	NOUN
chd-40	37	7	of	of	ADP
chd-40	37	8	prostate	prostate	NOUN
chd-40	37	9	cancer	cancer	NOUN
chd-40	37	10	cells	cell	NOUN
chd-40	37	11	and	and	CCONJ
chd-40	37	12	formation	formation	NOUN
chd-40	37	13	of	of	ADP
chd-40	37	14	endothelial	endothelial	ADJ
chd-40	37	15	cell	cell	NOUN
chd-40	37	16	tubes	tube	NOUN
chd-40	37	17	,	,	PUNCT
chd-40	37	18	and	and	CCONJ
chd-40	37	19	is	be	AUX
chd-40	37	20	positively	positively	ADV
chd-40	37	21	correlated	correlate	VERB
chd-40	37	22	with	with	ADP
chd-40	37	23	a	a	DET
chd-40	37	24	higher	high	ADJ
chd-40	37	25	gleason	gleason	NOUN
chd-40	37	26	score	score	NOUN
chd-40	37	27	(	(	PUNCT
chd-40	37	28	dozmorov	dozmorov	PROPN
chd-40	37	29	et	et	PROPN
chd-40	37	30	al	al	PROPN
chd-40	37	31	.	.	PROPN
chd-40	37	32	,	,	PUNCT
chd-40	37	33	2010	2010	NUM
chd-40	37	34	)	)	PUNCT
chd-40	37	35	.	.	PUNCT
chd-40	38	1	however	however	ADV
chd-40	38	2	,	,	PUNCT
chd-40	38	3	there	there	PRON
chd-40	38	4	were	be	VERB
chd-40	38	5	lower	low	ADJ
chd-40	38	6	expressions	expression	NOUN
chd-40	38	7	of	of	ADP
chd-40	38	8	akr1c3	akr1c3	PROPN
chd-40	38	9	in	in	ADP
chd-40	38	10	aa	aa	NOUN
chd-40	38	11	prostate	prostate	NOUN
chd-40	38	12	cancers	cancer	NOUN
chd-40	38	13	than	than	ADP
chd-40	38	14	in	in	ADP
chd-40	38	15	ca	ca	NOUN
chd-40	38	16	prostate	prostate	NOUN
chd-40	38	17	cancers	cancer	NOUN
chd-40	38	18	,	,	PUNCT
chd-40	38	19	which	which	PRON
chd-40	38	20	suggests	suggest	VERB
chd-40	38	21	a	a	DET
chd-40	38	22	contradictory	contradictory	ADJ
chd-40	38	23	function	function	NOUN
chd-40	38	24	of	of	ADP
chd-40	38	25	akr1c3	akr1c3	PROPN
chd-40	38	26	in	in	ADP
chd-40	38	27	racial	racial	ADJ
chd-40	38	28	disparities	disparity	NOUN
chd-40	38	29	between	between	ADP
chd-40	38	30	aa	aa	NOUN
chd-40	38	31	and	and	CCONJ
chd-40	38	32	ca	ca	NOUN
chd-40	38	33	men	man	NOUN
chd-40	38	34	.	.	PUNCT
chd-40	39	1	cyp3a5	cyp3a5	PROPN
chd-40	39	2	,	,	PUNCT
chd-40	39	3	which	which	PRON
chd-40	39	4	is	be	AUX
chd-40	39	5	involved	involve	VERB
chd-40	39	6	in	in	ADP
chd-40	39	7	hydroxylation	hydroxylation	NOUN
chd-40	39	8	of	of	ADP
chd-40	39	9	testosterone	testosterone	NOUN
chd-40	39	10	and	and	CCONJ
chd-40	39	11	dehydroepiandrosterone	dehydroepiandrosterone	PROPN
chd-40	39	12	(	(	PUNCT
chd-40	39	13	zeigler	zeigler	PROPN
chd-40	39	14	-	-	PUNCT
chd-40	39	15	johnson	johnson	PROPN
chd-40	39	16	et	et	PROPN
chd-40	39	17	al	al	PROPN
chd-40	39	18	.	.	PROPN
chd-40	39	19	,	,	PUNCT
chd-40	39	20	2013	2013	NUM
chd-40	39	21	)	)	PUNCT
chd-40	39	22	,	,	PUNCT
chd-40	39	23	enhances	enhance	VERB
chd-40	39	24	growth	growth	NOUN
chd-40	39	25	of	of	ADP
chd-40	39	26	prostate	prostate	NOUN
chd-40	39	27	cancer	cancer	NOUN
chd-40	39	28	cells	cell	NOUN
chd-40	39	29	through	through	ADP
chd-40	39	30	facilitating	facilitate	VERB
chd-40	39	31	the	the	DET
chd-40	39	32	nuclear	nuclear	ADJ
chd-40	39	33	translocation	translocation	NOUN
chd-40	39	34	of	of	ADP
chd-40	39	35	ar	ar	PROPN
chd-40	39	36	(	(	PUNCT
chd-40	39	37	mitra	mitra	PROPN
chd-40	39	38	and	and	CCONJ
chd-40	39	39	goodman	goodman	PROPN
chd-40	39	40	,	,	PUNCT
chd-40	39	41	2015	2015	NUM
chd-40	39	42	)	)	PUNCT
chd-40	39	43	.	.	PUNCT
chd-40	40	1	the	the	DET
chd-40	40	2	higher	high	ADJ
chd-40	40	3	expression	expression	NOUN
chd-40	40	4	cyp3a5	cyp3a5	NOUN
chd-40	40	5	in	in	ADP
chd-40	40	6	aa	aa	PROPN
chd-40	40	7	men	man	NOUN
chd-40	40	8	may	may	AUX
chd-40	40	9	be	be	AUX
chd-40	40	10	associated	associate	VERB
chd-40	40	11	with	with	ADP
chd-40	40	12	higher	high	ADJ
chd-40	40	13	ar	ar	NOUN
chd-40	40	14	levels	level	NOUN
chd-40	40	15	and	and	CCONJ
chd-40	40	16	a	a	DET
chd-40	40	17	higher	high	ADJ
chd-40	40	18	risk	risk	NOUN
chd-40	40	19	of	of	ADP
chd-40	40	20	prostate	prostate	NOUN
chd-40	40	21	cancer	cancer	NOUN
chd-40	40	22	(	(	PUNCT
chd-40	40	23	singh	singh	PROPN
chd-40	40	24	et	et	PROPN
chd-40	40	25	al	al	PROPN
chd-40	40	26	.	.	PROPN
chd-40	40	27	,	,	PUNCT
chd-40	40	28	2017	2017	NUM
chd-40	40	29	)	)	PUNCT
chd-40	40	30	.	.	PUNCT
chd-40	41	1	as	as	SCONJ
chd-40	41	2	shown	show	VERB
chd-40	41	3	here	here	ADV
chd-40	41	4	,	,	PUNCT
chd-40	41	5	there	there	PRON
chd-40	41	6	were	be	VERB
chd-40	41	7	higher	high	ADJ
chd-40	41	8	expression	expression	NOUN
chd-40	41	9	levels	level	NOUN
chd-40	41	10	          	          	SPACE
chd-40	41	11	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-40	41	12	e4	e4	PROPN
chd-40	41	13	cancer	cancer	NOUN
chd-40	41	14	health	health	NOUN
chd-40	41	15	disparities	disparity	NOUN
chd-40	41	16	  	  	SPACE
chd-40	41	17	research	research	NOUN
chd-40	41	18	of	of	ADP
chd-40	41	19	cyp3a5	cyp3a5	NOUN
chd-40	41	20	in	in	ADP
chd-40	41	21	aa	aa	NOUN
chd-40	41	22	prostate	prostate	NOUN
chd-40	41	23	cancers	cancer	NOUN
chd-40	41	24	compared	compare	VERB
chd-40	41	25	with	with	ADP
chd-40	41	26	ca	ca	NOUN
chd-40	41	27	prostate	prostate	NOUN
chd-40	41	28	cancers	cancer	NOUN
chd-40	41	29	,	,	PUNCT
chd-40	41	30	supporting	support	VERB
chd-40	41	31	the	the	DET
chd-40	41	32	previous	previous	ADJ
chd-40	41	33	observation	observation	NOUN
chd-40	41	34	and	and	CCONJ
chd-40	41	35	hypothesis	hypothesis	NOUN
chd-40	41	36	.	.	PUNCT
chd-40	42	1	in	in	ADP
chd-40	42	2	the	the	DET
chd-40	42	3	gonads	gonad	NOUN
chd-40	42	4	and	and	CCONJ
chd-40	42	5	adrenals	adrenal	NOUN
chd-40	42	6	,	,	PUNCT
chd-40	42	7	cyp17a1	cyp17a1	PROPN
chd-40	42	8	is	be	AUX
chd-40	42	9	involved	involve	VERB
chd-40	42	10	in	in	ADP
chd-40	42	11	various	various	ADJ
chd-40	42	12	pathways	pathway	NOUN
chd-40	42	13	of	of	ADP
chd-40	42	14	androgen	androgen	NOUN
chd-40	42	15	biosynthesis	biosynthesis	NOUN
chd-40	42	16	(	(	PUNCT
chd-40	42	17	bremmer	bremmer	NOUN
chd-40	42	18	et	et	PROPN
chd-40	42	19	al	al	PROPN
chd-40	42	20	.	.	PROPN
chd-40	42	21	,	,	PUNCT
chd-40	42	22	2014	2014	NUM
chd-40	42	23	)	)	PUNCT
chd-40	42	24	.	.	PUNCT
chd-40	43	1	although	although	SCONJ
chd-40	43	2	greater	great	ADJ
chd-40	43	3	expression	expression	NOUN
chd-40	43	4	of	of	ADP
chd-40	43	5	cyp17a1	cyp17a1	PROPN
chd-40	43	6	appears	appear	VERB
chd-40	43	7	to	to	PART
chd-40	43	8	correlate	correlate	VERB
chd-40	43	9	with	with	ADP
chd-40	43	10	higher	high	ADJ
chd-40	43	11	stages	stage	NOUN
chd-40	43	12	and	and	CCONJ
chd-40	43	13	shorter	short	ADJ
chd-40	43	14	relapse	relapse	NOUN
chd-40	43	15	-	-	PUNCT
chd-40	43	16	free	free	ADJ
chd-40	43	17	times	time	NOUN
chd-40	43	18	in	in	ADP
chd-40	43	19	prostate	prostate	NOUN
chd-40	43	20	cancer	cancer	NOUN
chd-40	43	21	(	(	PUNCT
chd-40	43	22	bremmer	bremmer	PROPN
chd-40	43	23	et	et	PROPN
chd-40	43	24	al	al	PROPN
chd-40	43	25	.	.	PROPN
chd-40	43	26	,	,	PUNCT
chd-40	43	27	2014	2014	NUM
chd-40	43	28	;	;	PUNCT
chd-40	43	29	gomez	gomez	PROPN
chd-40	43	30	et	et	PROPN
chd-40	43	31	al	al	PROPN
chd-40	43	32	.	.	PROPN
chd-40	43	33	,	,	PUNCT
chd-40	43	34	2015	2015	NUM
chd-40	43	35	;	;	PUNCT
chd-40	43	36	salvi	salvi	PROPN
chd-40	43	37	et	et	PROPN
chd-40	43	38	al	al	PROPN
chd-40	43	39	.	.	PROPN
chd-40	43	40	,	,	PUNCT
chd-40	43	41	2016	2016	NUM
chd-40	43	42	)	)	PUNCT
chd-40	43	43	,	,	PUNCT
chd-40	43	44	expression	expression	NOUN
chd-40	43	45	of	of	ADP
chd-40	43	46	the	the	DET
chd-40	43	47	cyp17a1	cyp17a1	PROPN
chd-40	43	48	gene	gene	NOUN
chd-40	43	49	was	be	AUX
chd-40	43	50	lower	low	ADJ
chd-40	43	51	in	in	ADP
chd-40	43	52	primary	primary	ADJ
chd-40	43	53	prostate	prostate	NOUN
chd-40	43	54	cancers	cancer	NOUN
chd-40	43	55	than	than	ADP
chd-40	43	56	in	in	ADP
chd-40	43	57	normal	normal	ADJ
chd-40	43	58	prostate	prostate	NOUN
chd-40	43	59	tissue	tissue	NOUN
chd-40	43	60	and	and	CCONJ
chd-40	43	61	was	be	AUX
chd-40	43	62	lower	low	ADJ
chd-40	43	63	in	in	ADP
chd-40	43	64	aa	aa	ADJ
chd-40	43	65	prostate	prostate	NOUN
chd-40	43	66	cancers	cancer	NOUN
chd-40	43	67	than	than	ADP
chd-40	43	68	in	in	ADP
chd-40	43	69	ca	ca	NOUN
chd-40	43	70	prostate	prostate	NOUN
chd-40	43	71	cancers	cancer	NOUN
chd-40	43	72	.	.	PUNCT
chd-40	44	1	although	although	SCONJ
chd-40	44	2	,	,	PUNCT
chd-40	44	3	for	for	ADP
chd-40	44	4	aa	aa	PROPN
chd-40	44	5	men	man	NOUN
chd-40	44	6	,	,	PUNCT
chd-40	44	7	a	a	DET
chd-40	44	8	dysfunction	dysfunction	NOUN
chd-40	44	9	of	of	ADP
chd-40	44	10	cyp17a1	cyp17a1	NOUN
chd-40	44	11	may	may	AUX
chd-40	44	12	affect	affect	VERB
chd-40	44	13	the	the	DET
chd-40	44	14	susceptibility	susceptibility	NOUN
chd-40	44	15	to	to	ADP
chd-40	44	16	prostate	prostate	NOUN
chd-40	44	17	cancer	cancer	NOUN
chd-40	44	18	,	,	PUNCT
chd-40	44	19	the	the	DET
chd-40	44	20	present	present	ADJ
chd-40	44	21	data	datum	NOUN
chd-40	44	22	do	do	AUX
chd-40	44	23	not	not	PART
chd-40	44	24	support	support	VERB
chd-40	44	25	the	the	DET
chd-40	44	26	concept	concept	NOUN
chd-40	44	27	that	that	SCONJ
chd-40	44	28	cyp17a1	cyp17a1	PROPN
chd-40	44	29	is	be	AUX
chd-40	44	30	a	a	DET
chd-40	44	31	regulator	regulator	NOUN
chd-40	44	32	for	for	ADP
chd-40	44	33	racial	racial	ADJ
chd-40	44	34	disparities	disparity	NOUN
chd-40	44	35	between	between	ADP
chd-40	44	36	aa	aa	NOUN
chd-40	44	37	men	man	NOUN
chd-40	44	38	and	and	CCONJ
chd-40	44	39	ca	ca	NOUN
chd-40	44	40	men	man	NOUN
chd-40	44	41	.	.	PUNCT
chd-40	45	1	hsd3b2	hsd3b2	PRON
chd-40	45	2	is	be	AUX
chd-40	45	3	involved	involve	VERB
chd-40	45	4	in	in	ADP
chd-40	45	5	catalyzing	catalyze	VERB
chd-40	45	6	androstendione	androstendione	NOUN
chd-40	45	7	and	and	CCONJ
chd-40	45	8	dht	dht	NOUN
chd-40	45	9	metabolites	metabolite	NOUN
chd-40	45	10	(	(	PUNCT
chd-40	45	11	simard	simard	PROPN
chd-40	45	12	et	et	PROPN
chd-40	45	13	al	al	PROPN
chd-40	45	14	.	.	PROPN
chd-40	45	15	,	,	PUNCT
chd-40	45	16	1996	1996	NUM
chd-40	45	17	)	)	PUNCT
chd-40	45	18	.	.	PUNCT
chd-40	46	1	higher	high	ADJ
chd-40	46	2	expression	expression	NOUN
chd-40	46	3	of	of	ADP
chd-40	46	4	hsd3b2	hsd3b2	PRON
chd-40	46	5	accelerates	accelerate	VERB
chd-40	46	6	the	the	DET
chd-40	46	7	degradation	degradation	NOUN
chd-40	46	8	of	of	ADP
chd-40	46	9	dht	dht	NOUN
chd-40	46	10	metabolites	metabolite	NOUN
chd-40	46	11	and	and	CCONJ
chd-40	46	12	leads	lead	VERB
chd-40	46	13	to	to	ADP
chd-40	46	14	lower	low	ADJ
chd-40	46	15	dht	dht	NOUN
chd-40	46	16	levels	level	NOUN
chd-40	46	17	(	(	PUNCT
chd-40	46	18	simard	simard	PROPN
chd-40	46	19	et	et	PROPN
chd-40	46	20	al	al	PROPN
chd-40	46	21	.	.	PROPN
chd-40	46	22	,	,	PUNCT
chd-40	46	23	1996	1996	NUM
chd-40	46	24	)	)	PUNCT
chd-40	46	25	.	.	PUNCT
chd-40	47	1	however	however	ADV
chd-40	47	2	,	,	PUNCT
chd-40	47	3	the	the	DET
chd-40	47	4	relationship	relationship	NOUN
chd-40	47	5	between	between	ADP
chd-40	47	6	high	high	ADJ
chd-40	47	7	dht	dht	NOUN
chd-40	47	8	levels	level	NOUN
chd-40	47	9	and	and	CCONJ
chd-40	47	10	prostate	prostate	NOUN
chd-40	47	11	cancer	cancer	NOUN
chd-40	47	12	risk	risk	NOUN
chd-40	47	13	is	be	AUX
chd-40	47	14	controversial	controversial	ADJ
chd-40	47	15	.	.	PUNCT
chd-40	48	1	for	for	ADP
chd-40	48	2	ca	ca	NOUN
chd-40	48	3	men	man	NOUN
chd-40	48	4	and	and	CCONJ
chd-40	48	5	aa	aa	NOUN
chd-40	48	6	men	man	NOUN
chd-40	48	7	,	,	PUNCT
chd-40	48	8	there	there	PRON
chd-40	48	9	are	be	VERB
chd-40	48	10	no	no	DET
chd-40	48	11	significant	significant	ADJ
chd-40	48	12	differences	difference	NOUN
chd-40	48	13	in	in	ADP
chd-40	48	14	dht	dht	NOUN
chd-40	48	15	levels	level	NOUN
chd-40	48	16	in	in	ADP
chd-40	48	17	sera	sera	NOUN
chd-40	48	18	and	and	CCONJ
chd-40	48	19	tissues	tissue	NOUN
chd-40	48	20	(	(	PUNCT
chd-40	48	21	singh	singh	PROPN
chd-40	48	22	et	et	PROPN
chd-40	48	23	al	al	PROPN
chd-40	48	24	.	.	PROPN
chd-40	48	25	,	,	PUNCT
chd-40	48	26	2017	2017	NUM
chd-40	48	27	)	)	PUNCT
chd-40	48	28	.	.	PUNCT
chd-40	49	1	the	the	DET
chd-40	49	2	present	present	ADJ
chd-40	49	3	data	datum	NOUN
chd-40	49	4	also	also	ADV
chd-40	49	5	showed	show	VERB
chd-40	49	6	higher	high	ADJ
chd-40	49	7	expression	expression	NOUN
chd-40	49	8	of	of	ADP
chd-40	49	9	hsd3b2	hsd3b2	PRON
chd-40	49	10	in	in	ADP
chd-40	49	11	aa	aa	NOUN
chd-40	49	12	prostate	prostate	NOUN
chd-40	49	13	cancers	cancer	NOUN
chd-40	49	14	compared	compare	VERB
chd-40	49	15	with	with	ADP
chd-40	49	16	ca	ca	NOUN
chd-40	49	17	prostate	prostate	NOUN
chd-40	49	18	cancers	cancer	NOUN
chd-40	49	19	,	,	PUNCT
chd-40	49	20	results	result	VERB
chd-40	49	21	that	that	PRON
chd-40	49	22	are	be	AUX
chd-40	49	23	inconsistent	inconsistent	ADJ
chd-40	49	24	with	with	ADP
chd-40	49	25	racial	racial	ADJ
chd-40	49	26	disparities	disparity	NOUN
chd-40	49	27	between	between	ADP
chd-40	49	28	aa	aa	NOUN
chd-40	49	29	and	and	CCONJ
chd-40	49	30	ca	ca	NOUN
chd-40	49	31	men	man	NOUN
chd-40	49	32	.	.	PUNCT
chd-40	50	1	srd5a2	srd5a2	NOUN
chd-40	50	2	is	be	AUX
chd-40	50	3	responsible	responsible	ADJ
chd-40	50	4	for	for	ADP
chd-40	50	5	the	the	DET
chd-40	50	6	conversion	conversion	NOUN
chd-40	50	7	of	of	ADP
chd-40	50	8	testosterone	testosterone	NOUN
chd-40	50	9	into	into	ADP
chd-40	50	10	dht	dht	PROPN
chd-40	50	11	(	(	PUNCT
chd-40	50	12	fang	fang	X
chd-40	50	13	et	et	PROPN
chd-40	50	14	al	al	PROPN
chd-40	50	15	.	.	PROPN
chd-40	50	16	,	,	PUNCT
chd-40	50	17	2017	2017	NUM
chd-40	50	18	)	)	PUNCT
chd-40	50	19	.	.	PUNCT
chd-40	51	1	genetic	genetic	ADJ
chd-40	51	2	analyses	analysis	NOUN
chd-40	51	3	suggest	suggest	VERB
chd-40	51	4	that	that	SCONJ
chd-40	51	5	there	there	PRON
chd-40	51	6	are	be	VERB
chd-40	51	7	srd5a2	srd5a2	NOUN
chd-40	51	8	ta	ta	PART
chd-40	51	9	repeat	repeat	VERB
chd-40	51	10	alleles	allele	NOUN
chd-40	51	11	in	in	ADP
chd-40	51	12	aa	aa	NOUN
chd-40	51	13	men	man	NOUN
chd-40	51	14	at	at	ADP
chd-40	51	15	high	high	ADJ
chd-40	51	16	risk	risk	NOUN
chd-40	51	17	for	for	ADP
chd-40	51	18	prostate	prostate	NOUN
chd-40	51	19	cancer	cancer	NOUN
chd-40	51	20	but	but	CCONJ
chd-40	51	21	not	not	PART
chd-40	51	22	in	in	ADP
chd-40	51	23	ca	ca	NOUN
chd-40	51	24	men	man	NOUN
chd-40	51	25	(	(	PUNCT
chd-40	51	26	singh	singh	PROPN
chd-40	51	27	et	et	PROPN
chd-40	51	28	al	al	PROPN
chd-40	51	29	.	.	PROPN
chd-40	51	30	,	,	PUNCT
chd-40	51	31	2017	2017	NUM
chd-40	51	32	)	)	PUNCT
chd-40	51	33	,	,	PUNCT
chd-40	51	34	indicating	indicate	VERB
chd-40	51	35	that	that	SCONJ
chd-40	51	36	genetic	genetic	ADJ
chd-40	51	37	variants	variant	NOUN
chd-40	51	38	of	of	ADP
chd-40	51	39	srd5a2	srd5a2	NOUN
chd-40	51	40	may	may	AUX
chd-40	51	41	be	be	AUX
chd-40	51	42	associated	associate	VERB
chd-40	51	43	with	with	ADP
chd-40	51	44	racial	racial	ADJ
chd-40	51	45	disparities	disparity	NOUN
chd-40	51	46	.	.	PUNCT
chd-40	52	1	variants	variant	NOUN
chd-40	52	2	of	of	ADP
chd-40	52	3	the	the	DET
chd-40	52	4	enzyme	enzyme	NOUN
chd-40	52	5	may	may	AUX
chd-40	52	6	enhance	enhance	VERB
chd-40	52	7	the	the	DET
chd-40	52	8	activity	activity	NOUN
chd-40	52	9	and	and	CCONJ
chd-40	52	10	result	result	VERB
chd-40	52	11	in	in	ADP
chd-40	52	12	higher	high	ADJ
chd-40	52	13	levels	level	NOUN
chd-40	52	14	of	of	ADP
chd-40	52	15	dht	dht	NOUN
chd-40	52	16	,	,	PUNCT
chd-40	52	17	leading	lead	VERB
chd-40	52	18	to	to	ADP
chd-40	52	19	cancer	cancer	NOUN
chd-40	52	20	progression	progression	NOUN
chd-40	52	21	.	.	PUNCT
chd-40	53	1	however	however	ADV
chd-40	53	2	,	,	PUNCT
chd-40	53	3	higher	high	ADJ
chd-40	53	4	expression	expression	NOUN
chd-40	53	5	of	of	ADP
chd-40	53	6	srd5a2	srd5a2	NOUN
chd-40	53	7	appears	appear	VERB
chd-40	53	8	to	to	PART
chd-40	53	9	be	be	AUX
chd-40	53	10	inconsistent	inconsistent	ADJ
chd-40	53	11	with	with	ADP
chd-40	53	12	higher	high	ADJ
chd-40	53	13	levels	level	NOUN
chd-40	53	14	of	of	ADP
chd-40	53	15	dht	dht	PROPN
chd-40	53	16	(	(	PUNCT
chd-40	53	17	singh	singh	PROPN
chd-40	53	18	et	et	PROPN
chd-40	53	19	al	al	PROPN
chd-40	53	20	.	.	PROPN
chd-40	53	21	,	,	PUNCT
chd-40	53	22	2017	2017	NUM
chd-40	53	23	)	)	PUNCT
chd-40	53	24	.	.	PUNCT
chd-40	54	1	the	the	DET
chd-40	54	2	present	present	ADJ
chd-40	54	3	data	datum	NOUN
chd-40	54	4	showed	show	VERB
chd-40	54	5	that	that	SCONJ
chd-40	54	6	expression	expression	NOUN
chd-40	54	7	of	of	ADP
chd-40	54	8	srd5a2	srd5a2	NOUN
chd-40	54	9	was	be	AUX
chd-40	54	10	lower	low	ADJ
chd-40	54	11	in	in	ADP
chd-40	54	12	aa	aa	ADJ
chd-40	54	13	prostate	prostate	NOUN
chd-40	54	14	cancers	cancer	NOUN
chd-40	54	15	compared	compare	VERB
chd-40	54	16	with	with	ADP
chd-40	54	17	those	those	PRON
chd-40	54	18	of	of	ADP
chd-40	54	19	cas	cas	PROPN
chd-40	54	20	,	,	PUNCT
chd-40	54	21	which	which	PRON
chd-40	54	22	does	do	AUX
chd-40	54	23	not	not	PART
chd-40	54	24	support	support	VERB
chd-40	54	25	a	a	DET
chd-40	54	26	role	role	NOUN
chd-40	54	27	of	of	ADP
chd-40	54	28	srd5a2	srd5a2	NOUN
chd-40	54	29	in	in	ADP
chd-40	54	30	the	the	DET
chd-40	54	31	racial	racial	ADJ
chd-40	54	32	disparities	disparity	NOUN
chd-40	54	33	between	between	ADP
chd-40	54	34	aa	aa	NOUN
chd-40	54	35	men	man	NOUN
chd-40	54	36	and	and	CCONJ
chd-40	54	37	ca	ca	NOUN
chd-40	54	38	men	man	NOUN
chd-40	54	39	.	.	PUNCT
chd-40	55	1	in	in	ADP
chd-40	55	2	the	the	DET
chd-40	55	3	androgen	androgen	NOUN
chd-40	55	4	biosynthesis	biosynthesis	NOUN
chd-40	55	5	pathway	pathway	NOUN
chd-40	55	6	,	,	PUNCT
chd-40	55	7	ugt2b15	ugt2b15	ADJ
chd-40	55	8	is	be	AUX
chd-40	55	9	a	a	DET
chd-40	55	10	regulator	regulator	NOUN
chd-40	55	11	for	for	ADP
chd-40	55	12	androstenedione	androstenedione	NOUN
chd-40	55	13	glucuronidate	glucuronidate	NOUN
chd-40	55	14	(	(	PUNCT
chd-40	55	15	gauthier	gauthier	NOUN
chd-40	55	16	-	-	PUNCT
chd-40	55	17	landry	landry	PROPN
chd-40	55	18	et	et	PROPN
chd-40	55	19	al	al	PROPN
chd-40	55	20	.	.	PROPN
chd-40	55	21	,	,	PUNCT
chd-40	55	22	2015	2015	NUM
chd-40	55	23	)	)	PUNCT
chd-40	55	24	.	.	PUNCT
chd-40	56	1	high	high	ADJ
chd-40	56	2	androstenedione	androstenedione	NOUN
chd-40	56	3	levels	level	NOUN
chd-40	56	4	may	may	AUX
chd-40	56	5	require	require	VERB
chd-40	56	6	more	more	ADJ
chd-40	56	7	glucuronosyltransferases	glucuronosyltransferase	NOUN
chd-40	56	8	encoded	encode	VERB
chd-40	56	9	by	by	ADP
chd-40	56	10	ugt2b15	ugt2b15	ADJ
chd-40	56	11	(	(	PUNCT
chd-40	56	12	singh	singh	PROPN
chd-40	56	13	et	et	PROPN
chd-40	56	14	al	al	PROPN
chd-40	56	15	.	.	PROPN
chd-40	56	16	,	,	PUNCT
chd-40	56	17	2017	2017	NUM
chd-40	56	18	)	)	PUNCT
chd-40	56	19	.	.	PUNCT
chd-40	57	1	of	of	ADP
chd-40	57	2	note	note	NOUN
chd-40	57	3	,	,	PUNCT
chd-40	57	4	there	there	PRON
chd-40	57	5	are	be	VERB
chd-40	57	6	higher	high	ADJ
chd-40	57	7	androstenedione	androstenedione	NOUN
chd-40	57	8	levels	level	NOUN
chd-40	57	9	in	in	ADP
chd-40	57	10	normal	normal	ADJ
chd-40	57	11	prostate	prostate	NOUN
chd-40	57	12	tissues	tissue	NOUN
chd-40	57	13	and	and	CCONJ
chd-40	57	14	greater	great	ADJ
chd-40	57	15	expression	expression	NOUN
chd-40	57	16	of	of	ADP
chd-40	57	17	ugt2b15	ugt2b15	ADJ
chd-40	57	18	in	in	ADP
chd-40	57	19	aa	aa	NOUN
chd-40	57	20	prostate	prostate	NOUN
chd-40	57	21	cancers	cancer	NOUN
chd-40	57	22	than	than	ADP
chd-40	57	23	in	in	ADP
chd-40	57	24	those	those	PRON
chd-40	57	25	of	of	ADP
chd-40	57	26	cas	cas	PROPN
chd-40	57	27	(	(	PUNCT
chd-40	57	28	singh	singh	PROPN
chd-40	57	29	et	et	PROPN
chd-40	57	30	al	al	PROPN
chd-40	57	31	.	.	PROPN
chd-40	57	32	,	,	PUNCT
chd-40	57	33	2017	2017	NUM
chd-40	57	34	)	)	PUNCT
chd-40	57	35	.	.	PUNCT
chd-40	58	1	as	as	SCONJ
chd-40	58	2	shown	show	VERB
chd-40	58	3	here	here	ADV
chd-40	58	4	,	,	PUNCT
chd-40	58	5	there	there	PRON
chd-40	58	6	was	be	VERB
chd-40	58	7	higher	high	ADJ
chd-40	58	8	expression	expression	NOUN
chd-40	58	9	of	of	ADP
chd-40	58	10	ugt2b15	ugt2b15	ADJ
chd-40	58	11	in	in	ADP
chd-40	58	12	aa	aa	NOUN
chd-40	58	13	prostate	prostate	NOUN
chd-40	58	14	cancers	cancer	NOUN
chd-40	58	15	compared	compare	VERB
chd-40	58	16	with	with	ADP
chd-40	58	17	ca	ca	NOUN
chd-40	58	18	prostate	prostate	NOUN
chd-40	58	19	cancers	cancer	NOUN
chd-40	58	20	,	,	PUNCT
chd-40	58	21	supporting	support	VERB
chd-40	58	22	a	a	DET
chd-40	58	23	function	function	NOUN
chd-40	58	24	of	of	ADP
chd-40	58	25	ugt2b15	ugt2b15	ADJ
chd-40	58	26	in	in	ADP
chd-40	58	27	racial	racial	ADJ
chd-40	58	28	disparities	disparity	NOUN
chd-40	58	29	of	of	ADP
chd-40	58	30	prostate	prostate	NOUN
chd-40	58	31	cancers	cancer	NOUN
chd-40	58	32	.	.	PUNCT
chd-40	59	1	since	since	SCONJ
chd-40	59	2	prostate	prostate	NOUN
chd-40	59	3	cancer	cancer	NOUN
chd-40	59	4	is	be	AUX
chd-40	59	5	a	a	DET
chd-40	59	6	pathophysiologic	pathophysiologic	ADJ
chd-40	59	7	disease	disease	NOUN
chd-40	59	8	involving	involve	VERB
chd-40	59	9	a	a	DET
chd-40	59	10	variety	variety	NOUN
chd-40	59	11	of	of	ADP
chd-40	59	12	genetic	genetic	ADJ
chd-40	59	13	factors	factor	NOUN
chd-40	59	14	(	(	PUNCT
chd-40	59	15	chang	chang	PROPN
chd-40	59	16	et	et	PROPN
chd-40	59	17	al	al	PROPN
chd-40	59	18	.	.	PROPN
chd-40	59	19	,	,	PUNCT
chd-40	59	20	2014	2014	NUM
chd-40	59	21	;	;	PUNCT
chd-40	59	22	cooper	cooper	NOUN
chd-40	59	23	and	and	CCONJ
chd-40	59	24	page	page	NOUN
chd-40	59	25	,	,	PUNCT
chd-40	59	26	2014	2014	NUM
chd-40	59	27	)	)	PUNCT
chd-40	59	28	,	,	PUNCT
chd-40	59	29	the	the	DET
chd-40	59	30	change	change	NOUN
chd-40	59	31	of	of	ADP
chd-40	59	32	a	a	DET
chd-40	59	33	single	single	ADJ
chd-40	59	34	gene	gene	NOUN
chd-40	59	35	may	may	AUX
chd-40	59	36	be	be	AUX
chd-40	59	37	insufficient	insufficient	ADJ
chd-40	59	38	to	to	PART
chd-40	59	39	produce	produce	VERB
chd-40	59	40	racial	racial	ADJ
chd-40	59	41	disparities	disparity	NOUN
chd-40	59	42	.	.	PUNCT
chd-40	60	1	further	far	ADV
chd-40	60	2	,	,	PUNCT
chd-40	60	3	the	the	DET
chd-40	60	4	functions	function	NOUN
chd-40	60	5	of	of	ADP
chd-40	60	6	genes	gene	NOUN
chd-40	60	7	in	in	ADP
chd-40	60	8	racial	racial	ADJ
chd-40	60	9	disparities	disparity	NOUN
chd-40	60	10	in	in	ADP
chd-40	60	11	prostate	prostate	NOUN
chd-40	60	12	cancer	cancer	NOUN
chd-40	60	13	are	be	AUX
chd-40	60	14	associated	associate	VERB
chd-40	60	15	with	with	ADP
chd-40	60	16	mrna	mrna	NOUN
chd-40	60	17	and	and	CCONJ
chd-40	60	18	protein	protein	NOUN
chd-40	60	19	expression	expression	NOUN
chd-40	60	20	.	.	PUNCT
chd-40	61	1	moreover	moreover	ADV
chd-40	61	2	,	,	PUNCT
chd-40	61	3	the	the	DET
chd-40	61	4	aa	aa	PROPN
chd-40	61	5	cohort	cohort	NOUN
chd-40	61	6	of	of	ADP
chd-40	61	7	prostate	prostate	NOUN
chd-40	61	8	cancers	cancer	NOUN
chd-40	61	9	in	in	ADP
chd-40	61	10	this	this	DET
chd-40	61	11	tcga	tcga	ADJ
chd-40	61	12	database	database	NOUN
chd-40	61	13	includes	include	VERB
chd-40	61	14	only	only	ADV
chd-40	61	15	six	six	NUM
chd-40	61	16	cases	case	NOUN
chd-40	61	17	,	,	PUNCT
chd-40	61	18	which	which	PRON
chd-40	61	19	limits	limit	VERB
chd-40	61	20	the	the	DET
chd-40	61	21	statistical	statistical	ADJ
chd-40	61	22	power	power	NOUN
chd-40	61	23	to	to	PART
chd-40	61	24	detect	detect	VERB
chd-40	61	25	significant	significant	ADJ
chd-40	61	26	differences	difference	NOUN
chd-40	61	27	in	in	ADP
chd-40	61	28	our	our	PRON
chd-40	61	29	analysis	analysis	NOUN
chd-40	61	30	.	.	PUNCT
chd-40	62	1	therefore	therefore	ADV
chd-40	62	2	,	,	PUNCT
chd-40	62	3	a	a	DET
chd-40	62	4	larger	large	ADJ
chd-40	62	5	sample	sample	NOUN
chd-40	62	6	cohort	cohort	NOUN
chd-40	62	7	is	be	AUX
chd-40	62	8	needed	need	VERB
chd-40	62	9	to	to	PART
chd-40	62	10	establish	establish	VERB
chd-40	62	11	the	the	DET
chd-40	62	12	relationship	relationship	NOUN
chd-40	62	13	between	between	ADP
chd-40	62	14	the	the	DET
chd-40	62	15	genes	gene	NOUN
chd-40	62	16	and	and	CCONJ
chd-40	62	17	racial	racial	ADJ
chd-40	62	18	disparities	disparity	NOUN
chd-40	62	19	in	in	ADP
chd-40	62	20	prostate	prostate	NOUN
chd-40	62	21	cancer	cancer	NOUN
chd-40	62	22	.	.	PUNCT
chd-40	63	1	in	in	ADP
chd-40	63	2	summary	summary	NOUN
chd-40	63	3	,	,	PUNCT
chd-40	63	4	in	in	ADP
chd-40	63	5	the	the	DET
chd-40	63	6	united	united	PROPN
chd-40	63	7	states	states	PROPN
chd-40	63	8	,	,	PUNCT
chd-40	63	9	the	the	DET
chd-40	63	10	incidences	incidence	NOUN
chd-40	63	11	of	of	ADP
chd-40	63	12	prostate	prostate	NOUN
chd-40	63	13	cancer	cancer	NOUN
chd-40	63	14	are	be	AUX
chd-40	63	15	different	different	ADJ
chd-40	63	16	for	for	ADP
chd-40	63	17	ca	ca	NOUN
chd-40	63	18	and	and	CCONJ
chd-40	63	19	aa	aa	PROPN
chd-40	63	20	men	man	NOUN
chd-40	63	21	.	.	PUNCT
chd-40	64	1	genes	gene	NOUN
chd-40	64	2	,	,	PUNCT
chd-40	64	3	such	such	ADJ
chd-40	64	4	as	as	ADP
chd-40	64	5	cyp3a5	cyp3a5	NOUN
chd-40	64	6	and	and	CCONJ
chd-40	64	7	ugt2b15	ugt2b15	ADJ
chd-40	64	8	,	,	PUNCT
chd-40	64	9	which	which	PRON
chd-40	64	10	are	be	AUX
chd-40	64	11	involved	involve	VERB
chd-40	64	12	in	in	ADP
chd-40	64	13	androgen	androgen	NOUN
chd-40	64	14	metabolism	metabolism	NOUN
chd-40	64	15	,	,	PUNCT
chd-40	64	16	appear	appear	VERB
chd-40	64	17	to	to	PART
chd-40	64	18	be	be	AUX
chd-40	64	19	associated	associate	VERB
chd-40	64	20	with	with	ADP
chd-40	64	21	racial	racial	ADJ
chd-40	64	22	disparities	disparity	NOUN
chd-40	64	23	between	between	ADP
chd-40	64	24	aa	aa	NOUN
chd-40	64	25	and	and	CCONJ
chd-40	64	26	ca	can	AUX
chd-40	64	27	prostate	prostate	NOUN
chd-40	64	28	cancers	cancer	NOUN
chd-40	64	29	.	.	PUNCT
chd-40	65	1	due	due	ADP
chd-40	65	2	to	to	ADP
chd-40	65	3	a	a	DET
chd-40	65	4	limitation	limitation	NOUN
chd-40	65	5	of	of	ADP
chd-40	65	6	sample	sample	NOUN
chd-40	65	7	size	size	NOUN
chd-40	65	8	,	,	PUNCT
chd-40	65	9	however	however	ADV
chd-40	65	10	,	,	PUNCT
chd-40	65	11	the	the	DET
chd-40	65	12	results	result	NOUN
chd-40	65	13	need	need	VERB
chd-40	65	14	to	to	PART
chd-40	65	15	be	be	AUX
chd-40	65	16	validated	validate	VERB
chd-40	65	17	in	in	ADP
chd-40	65	18	further	further	ADJ
chd-40	65	19	studies	study	NOUN
chd-40	65	20	.	.	PUNCT
chd-40	66	1	acknowledgements	acknowledgement	NOUN
chd-40	66	2	we	we	PRON
chd-40	66	3	thank	thank	VERB
chd-40	66	4	dr	dr	PROPN
chd-40	66	5	.	.	PROPN
chd-40	66	6	donald	donald	PROPN
chd-40	66	7	l.	l.	PROPN
chd-40	66	8	hill	hill	PROPN
chd-40	66	9	for	for	ADP
chd-40	66	10	editorial	editorial	ADJ
chd-40	66	11	assistance	assistance	NOUN
chd-40	66	12	in	in	ADP
chd-40	66	13	preparing	prepare	VERB
chd-40	66	14	this	this	DET
chd-40	66	15	manuscript	manuscript	NOUN
chd-40	66	16	.	.	PUNCT
chd-40	67	1	this	this	DET
chd-40	67	2	work	work	NOUN
chd-40	67	3	was	be	AUX
chd-40	67	4	supported	support	VERB
chd-40	67	5	by	by	ADP
chd-40	67	6	the	the	DET
chd-40	67	7	national	national	PROPN
chd-40	67	8	institutes	institutes	PROPN
chd-40	67	9	of	of	ADP
chd-40	67	10	health	health	PROPN
chd-40	67	11	/	/	SYM
chd-40	67	12	national	national	PROPN
chd-40	67	13	cancer	cancer	PROPN
chd-40	67	14	institute	institute	PROPN
chd-40	67	15	(	(	PUNCT
chd-40	67	16	ca179282	ca179282	PROPN
chd-40	67	17	and	and	CCONJ
chd-40	67	18	          	          	SPACE
chd-40	67	19	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-40	67	20	e5	e5	PROPN
chd-40	67	21	cancer	cancer	NOUN
chd-40	67	22	health	health	NOUN
chd-40	67	23	disparities	disparity	NOUN
chd-40	67	24	  	  	SPACE
chd-40	67	25	research	research	NOUN
chd-40	67	26	ca118948	ca118948	PROPN
chd-40	67	27	)	)	PUNCT
chd-40	67	28	and	and	CCONJ
chd-40	67	29	the	the	DET
chd-40	67	30	department	department	NOUN
chd-40	67	31	of	of	ADP
chd-40	67	32	defense	defense	PROPN
chd-40	67	33	(	(	PUNCT
chd-40	67	34	pc130594	pc130594	NOUN
chd-40	67	35	and	and	CCONJ
chd-40	67	36	pc140308	pc140308	NOUN
chd-40	67	37	)	)	PUNCT
chd-40	67	38	.	.	PUNCT
chd-40	68	1	conflict	conflict	NOUN
chd-40	68	2	of	of	ADP
chd-40	68	3	interest	interest	NOUN
chd-40	68	4	statement	statement	NOUN
chd-40	68	5	the	the	DET
chd-40	68	6	author	author	NOUN
chd-40	68	7	has	have	AUX
chd-40	68	8	declared	declare	VERB
chd-40	68	9	that	that	SCONJ
chd-40	68	10	no	no	DET
chd-40	68	11	competing	compete	VERB
chd-40	68	12	or	or	CCONJ
chd-40	68	13	conflict	conflict	NOUN
chd-40	68	14	of	of	ADP
chd-40	68	15	interests	interest	NOUN
chd-40	68	16	exist	exist	VERB
chd-40	68	17	.	.	PUNCT
chd-40	69	1	the	the	DET
chd-40	69	2	funders	funder	NOUN
chd-40	69	3	had	have	VERB
chd-40	69	4	no	no	DET
chd-40	69	5	role	role	NOUN
chd-40	69	6	in	in	ADP
chd-40	69	7	study	study	NOUN
chd-40	69	8	design	design	NOUN
chd-40	69	9	,	,	PUNCT
chd-40	69	10	writing	writing	NOUN
chd-40	69	11	of	of	ADP
chd-40	69	12	the	the	DET
chd-40	69	13	manuscript	manuscript	NOUN
chd-40	69	14	and	and	CCONJ
chd-40	69	15	decision	decision	NOUN
chd-40	69	16	to	to	PART
chd-40	69	17	publish	publish	VERB
chd-40	69	18	.	.	PUNCT
chd-40	70	1	authors	author	NOUN
chd-40	70	2	’	’	PART
chd-40	70	3	contributions	contribution	NOUN
chd-40	70	4	wl	wl	PROPN
chd-40	70	5	performed	perform	VERB
chd-40	70	6	the	the	DET
chd-40	70	7	analyses	analysis	NOUN
chd-40	70	8	.	.	PUNCT
chd-40	71	1	rl	rl	VERB
chd-40	71	2	and	and	CCONJ
chd-40	71	3	lw	lw	PROPN
chd-40	71	4	wrote	write	VERB
chd-40	71	5	the	the	DET
chd-40	71	6	manuscript	manuscript	NOUN
chd-40	71	7	.	.	PUNCT
chd-40	72	1	references	reference	NOUN
chd-40	72	2	bremmer	bremmer	PROPN
chd-40	72	3	,	,	PUNCT
chd-40	72	4	f.	f.	PROPN
chd-40	72	5	,	,	PUNCT
chd-40	72	6	jarry	jarry	PROPN
chd-40	72	7	,	,	PUNCT
chd-40	72	8	h.	h.	PROPN
chd-40	72	9	,	,	PUNCT
chd-40	72	10	strauss	strauss	PROPN
chd-40	72	11	,	,	PUNCT
chd-40	72	12	a.	a.	PROPN
chd-40	72	13	,	,	PUNCT
chd-40	72	14	behnes	behne	NOUN
chd-40	72	15	,	,	PUNCT
chd-40	72	16	c.l	c.l	PROPN
chd-40	72	17	.	.	PROPN
chd-40	72	18	,	,	PUNCT
chd-40	72	19	trojan	trojan	PROPN
chd-40	72	20	,	,	PUNCT
chd-40	72	21	l.	l.	PROPN
chd-40	72	22	,	,	PUNCT
chd-40	72	23	and	and	CCONJ
chd-40	72	24	thelen	thelen	VERB
chd-40	72	25	,	,	PUNCT
chd-40	72	26	p.	p.	NOUN
chd-40	72	27	(	(	PUNCT
chd-40	72	28	2014	2014	NUM
chd-40	72	29	)	)	PUNCT
chd-40	72	30	.	.	PUNCT
chd-40	73	1	increased	increase	VERB
chd-40	73	2	expression	expression	NOUN
chd-40	73	3	of	of	ADP
chd-40	73	4	cyp17a1	cyp17a1	PROPN
chd-40	73	5	indicates	indicate	VERB
chd-40	73	6	an	an	DET
chd-40	73	7	effective	effective	ADJ
chd-40	73	8	targeting	targeting	NOUN
chd-40	73	9	of	of	ADP
chd-40	73	10	the	the	DET
chd-40	73	11	androgen	androgen	NOUN
chd-40	73	12	receptor	receptor	NOUN
chd-40	73	13	axis	axis	NOUN
chd-40	73	14	in	in	ADP
chd-40	73	15	castration	castration	NOUN
chd-40	73	16	resistant	resistant	ADJ
chd-40	73	17	prostate	prostate	NOUN
chd-40	73	18	cancer	cancer	NOUN
chd-40	73	19	(	(	PUNCT
chd-40	73	20	crpc	crpc	ADJ
chd-40	73	21	)	)	PUNCT
chd-40	73	22	.	.	PUNCT
chd-40	74	1	springerplus	springerplus	PROPN
chd-40	74	2	3	3	NUM
chd-40	74	3	,	,	PUNCT
chd-40	74	4	574	574	NUM
chd-40	74	5	.	.	PUNCT
chd-40	75	1	chandrashekar	chandrashekar	PROPN
chd-40	75	2	,	,	PUNCT
chd-40	75	3	d.s	d.s	PROPN
chd-40	75	4	.	.	PROPN
chd-40	75	5	,	,	PUNCT
chd-40	75	6	bashel	bashel	PROPN
chd-40	75	7	,	,	PUNCT
chd-40	75	8	b.	b.	PROPN
chd-40	75	9	,	,	PUNCT
chd-40	75	10	balasubramanya	balasubramanya	PROPN
chd-40	75	11	,	,	PUNCT
chd-40	75	12	s.a.h	s.a.h	PROPN
chd-40	75	13	.	.	PROPN
chd-40	75	14	,	,	PUNCT
chd-40	75	15	creighton	creighton	PROPN
chd-40	75	16	,	,	PUNCT
chd-40	75	17	c.j	c.j	PROPN
chd-40	75	18	.	.	PROPN
chd-40	75	19	,	,	PUNCT
chd-40	75	20	ponce	ponce	PROPN
chd-40	75	21	-	-	PUNCT
chd-40	75	22	rodriguez	rodriguez	PROPN
chd-40	75	23	,	,	PUNCT
chd-40	75	24	i.	i.	NOUN
chd-40	75	25	,	,	PUNCT
chd-40	75	26	chakravarthi	chakravarthi	NOUN
chd-40	75	27	,	,	PUNCT
chd-40	75	28	b.	b.	PROPN
chd-40	75	29	,	,	PUNCT
chd-40	75	30	and	and	CCONJ
chd-40	75	31	varambally	varambally	ADV
chd-40	75	32	,	,	PUNCT
chd-40	75	33	s.	s.	PROPN
chd-40	75	34	(	(	PUNCT
chd-40	75	35	2017	2017	NUM
chd-40	75	36	)	)	PUNCT
chd-40	75	37	.	.	PUNCT
chd-40	76	1	ualcan	ualcan	ADJ
chd-40	76	2	:	:	PUNCT
chd-40	76	3	a	a	DET
chd-40	76	4	portal	portal	NOUN
chd-40	76	5	for	for	ADP
chd-40	76	6	facilitating	facilitate	VERB
chd-40	76	7	tumor	tumor	NOUN
chd-40	76	8	subgroup	subgroup	NOUN
chd-40	76	9	gene	gene	NOUN
chd-40	76	10	expression	expression	NOUN
chd-40	76	11	and	and	CCONJ
chd-40	76	12	survival	survival	NOUN
chd-40	76	13	analyses	analysis	NOUN
chd-40	76	14	.	.	PUNCT
chd-40	77	1	neoplasia	neoplasia	NOUN
chd-40	77	2	19	19	NUM
chd-40	77	3	,	,	PUNCT
chd-40	77	4	649	649	NUM
chd-40	77	5	-	-	SYM
chd-40	77	6	658	658	NUM
chd-40	77	7	.	.	PUNCT
chd-40	78	1	chang	chang	PROPN
chd-40	78	2	,	,	PUNCT
chd-40	78	3	k.h	k.h	PROPN
chd-40	78	4	.	.	PROPN
chd-40	78	5	,	,	PUNCT
chd-40	78	6	ercole	ercole	PROPN
chd-40	78	7	,	,	PUNCT
chd-40	78	8	c.e	c.e	PROPN
chd-40	78	9	.	.	PROPN
chd-40	78	10	,	,	PUNCT
chd-40	78	11	and	and	CCONJ
chd-40	78	12	sharifi	sharifi	NOUN
chd-40	78	13	,	,	PUNCT
chd-40	78	14	n.	n.	NOUN
chd-40	78	15	(	(	PUNCT
chd-40	78	16	2014	2014	NUM
chd-40	78	17	)	)	PUNCT
chd-40	78	18	.	.	PUNCT
chd-40	79	1	androgen	androgen	NOUN
chd-40	79	2	metabolism	metabolism	NOUN
chd-40	79	3	in	in	ADP
chd-40	79	4	prostate	prostate	NOUN
chd-40	79	5	cancer	cancer	NOUN
chd-40	79	6	:	:	PUNCT
chd-40	79	7	from	from	ADP
chd-40	79	8	molecular	molecular	ADJ
chd-40	79	9	mechanisms	mechanism	NOUN
chd-40	79	10	to	to	ADP
chd-40	79	11	clinical	clinical	ADJ
chd-40	79	12	consequences	consequence	NOUN
chd-40	79	13	.	.	PUNCT
chd-40	80	1	br	br	PROPN
chd-40	80	2	j	j	PROPN
chd-40	80	3	cancer	cancer	NOUN
chd-40	80	4	111	111	NUM
chd-40	80	5	,	,	PUNCT
chd-40	80	6	1249	1249	NUM
chd-40	80	7	-	-	SYM
chd-40	80	8	1254	1254	NUM
chd-40	80	9	.	.	PUNCT
chd-40	81	1	cooper	cooper	PROPN
chd-40	81	2	,	,	PUNCT
chd-40	81	3	l.a	l.a	PROPN
chd-40	81	4	.	.	PROPN
chd-40	81	5	,	,	PUNCT
chd-40	81	6	and	and	CCONJ
chd-40	81	7	page	page	NOUN
chd-40	81	8	,	,	PUNCT
chd-40	81	9	s.t	s.t	PROPN
chd-40	81	10	.	.	PROPN
chd-40	81	11	(	(	PUNCT
chd-40	81	12	2014	2014	NUM
chd-40	81	13	)	)	PUNCT
chd-40	81	14	.	.	PUNCT
chd-40	82	1	androgens	androgen	NOUN
chd-40	82	2	and	and	CCONJ
chd-40	82	3	prostate	prostate	NOUN
chd-40	82	4	disease	disease	NOUN
chd-40	82	5	.	.	PUNCT
chd-40	83	1	asian	asian	PROPN
chd-40	83	2	j	j	PROPN
chd-40	83	3	androl	androl	PROPN
chd-40	83	4	16	16	NUM
chd-40	83	5	,	,	PUNCT
chd-40	83	6	248255	248255	NUM
chd-40	83	7	.	.	PUNCT
chd-40	84	1	dozmorov	dozmorov	ADJ
chd-40	84	2	,	,	PUNCT
chd-40	84	3	m.g	m.g	PROPN
chd-40	84	4	.	.	PROPN
chd-40	84	5	,	,	PUNCT
chd-40	84	6	azzarello	azzarello	PROPN
chd-40	84	7	,	,	PUNCT
chd-40	84	8	j.t	j.t	PROPN
chd-40	84	9	.	.	PROPN
chd-40	84	10	,	,	PUNCT
chd-40	84	11	wren	wren	PROPN
chd-40	84	12	,	,	PUNCT
chd-40	84	13	j.d	j.d	PROPN
chd-40	84	14	.	.	PROPN
chd-40	84	15	,	,	PUNCT
chd-40	84	16	fung	fung	PROPN
chd-40	84	17	,	,	PUNCT
chd-40	84	18	k.m	k.m	PROPN
chd-40	84	19	.	.	PROPN
chd-40	84	20	,	,	PUNCT
chd-40	84	21	yang	yang	PROPN
chd-40	84	22	,	,	PUNCT
chd-40	84	23	q.	q.	PROPN
chd-40	84	24	,	,	PUNCT
chd-40	84	25	davis	davis	PROPN
chd-40	84	26	,	,	PUNCT
chd-40	84	27	j.s	j.s	PROPN
chd-40	84	28	.	.	PROPN
chd-40	84	29	,	,	PUNCT
chd-40	84	30	hurst	hurst	PROPN
chd-40	84	31	,	,	PUNCT
chd-40	84	32	r.e	r.e	PROPN
chd-40	84	33	.	.	PROPN
chd-40	84	34	,	,	PUNCT
chd-40	84	35	culkin	culkin	PROPN
chd-40	84	36	,	,	PUNCT
chd-40	84	37	d.j	d.j	PROPN
chd-40	84	38	.	.	PROPN
chd-40	84	39	,	,	PUNCT
chd-40	84	40	penning	penning	NOUN
chd-40	84	41	,	,	PUNCT
chd-40	84	42	t.m	t.m	PROPN
chd-40	84	43	.	.	PROPN
chd-40	84	44	,	,	PUNCT
chd-40	84	45	and	and	CCONJ
chd-40	84	46	lin	lin	PROPN
chd-40	84	47	,	,	PUNCT
chd-40	84	48	h.k	h.k	PROPN
chd-40	84	49	.	.	PROPN
chd-40	84	50	(	(	PUNCT
chd-40	84	51	2010	2010	NUM
chd-40	84	52	)	)	PUNCT
chd-40	84	53	.	.	PUNCT
chd-40	85	1	elevated	elevate	VERB
chd-40	85	2	akr1c3	akr1c3	DET
chd-40	85	3	expression	expression	NOUN
chd-40	85	4	promotes	promote	VERB
chd-40	85	5	prostate	prostate	NOUN
chd-40	85	6	cancer	cancer	NOUN
chd-40	85	7	cell	cell	NOUN
chd-40	85	8	survival	survival	NOUN
chd-40	85	9	and	and	CCONJ
chd-40	85	10	prostate	prostate	NOUN
chd-40	85	11	cellmediated	cellmediate	VERB
chd-40	85	12	endothelial	endothelial	ADJ
chd-40	85	13	cell	cell	NOUN
chd-40	85	14	tube	tube	NOUN
chd-40	85	15	formation	formation	NOUN
chd-40	85	16	:	:	PUNCT
chd-40	85	17	implications	implication	NOUN
chd-40	85	18	for	for	ADP
chd-40	85	19	prostate	prostate	NOUN
chd-40	85	20	cancer	cancer	NOUN
chd-40	85	21	progression	progression	NOUN
chd-40	85	22	.	.	PUNCT
chd-40	86	1	bmc	bmc	ADJ
chd-40	86	2	cancer	cancer	NOUN
chd-40	86	3	10	10	NUM
chd-40	86	4	,	,	PUNCT
chd-40	86	5	672	672	NUM
chd-40	86	6	.	.	PUNCT
chd-40	87	1	ellis	ellis	PROPN
chd-40	87	2	,	,	PUNCT
chd-40	87	3	l.	l.	PROPN
chd-40	87	4	,	,	PUNCT
chd-40	87	5	and	and	CCONJ
chd-40	87	6	nyborg	nyborg	ADJ
chd-40	87	7	,	,	PUNCT
chd-40	87	8	h.	h.	PROPN
chd-40	87	9	(	(	PUNCT
chd-40	87	10	1992	1992	NUM
chd-40	87	11	)	)	PUNCT
chd-40	87	12	.	.	PUNCT
chd-40	88	1	racial	racial	ADJ
chd-40	88	2	/	/	SYM
chd-40	88	3	ethnic	ethnic	ADJ
chd-40	88	4	variations	variation	NOUN
chd-40	88	5	in	in	ADP
chd-40	88	6	male	male	ADJ
chd-40	88	7	testosterone	testosterone	NOUN
chd-40	88	8	levels	level	NOUN
chd-40	88	9	:	:	PUNCT
chd-40	88	10	a	a	DET
chd-40	88	11	probable	probable	ADJ
chd-40	88	12	contributor	contributor	NOUN
chd-40	88	13	to	to	ADP
chd-40	88	14	group	group	NOUN
chd-40	88	15	differences	difference	NOUN
chd-40	88	16	in	in	ADP
chd-40	88	17	health	health	NOUN
chd-40	88	18	.	.	PUNCT
chd-40	89	1	steroids	steroid	NOUN
chd-40	89	2	57	57	NUM
chd-40	89	3	,	,	PUNCT
chd-40	89	4	72	72	NUM
chd-40	89	5	-	-	SYM
chd-40	89	6	75	75	NUM
chd-40	89	7	.	.	PUNCT
chd-40	90	1	fang	fang	PROPN
chd-40	90	2	,	,	PUNCT
chd-40	90	3	c.	c.	PROPN
chd-40	90	4	,	,	PUNCT
chd-40	90	5	guo	guo	PROPN
chd-40	90	6	,	,	PUNCT
chd-40	90	7	z.q	z.q	PROPN
chd-40	90	8	.	.	PROPN
chd-40	90	9	,	,	PUNCT
chd-40	90	10	chen	chen	PROPN
chd-40	90	11	,	,	PUNCT
chd-40	90	12	x.y	x.y	PROPN
chd-40	90	13	.	.	PROPN
chd-40	90	14	,	,	PUNCT
chd-40	90	15	liu	liu	PROPN
chd-40	90	16	,	,	PUNCT
chd-40	90	17	t.z	t.z	PROPN
chd-40	90	18	.	.	PROPN
chd-40	90	19	,	,	PUNCT
chd-40	90	20	zeng	zeng	PROPN
chd-40	90	21	,	,	PUNCT
chd-40	90	22	x.t	x.t	PROPN
chd-40	90	23	.	.	PROPN
chd-40	90	24	,	,	PUNCT
chd-40	90	25	and	and	CCONJ
chd-40	90	26	wang	wang	PROPN
chd-40	90	27	,	,	PUNCT
chd-40	90	28	x.h	x.h	PROPN
chd-40	90	29	.	.	PROPN
chd-40	90	30	(	(	PUNCT
chd-40	90	31	2017	2017	NUM
chd-40	90	32	)	)	PUNCT
chd-40	90	33	.	.	PUNCT
chd-40	91	1	relationship	relationship	NOUN
chd-40	91	2	between	between	ADP
chd-40	91	3	srd5a2	srd5a2	NOUN
chd-40	91	4	rs9282858	rs9282858	NOUN
chd-40	91	5	polymorphism	polymorphism	NOUN
chd-40	91	6	and	and	CCONJ
chd-40	91	7	the	the	DET
chd-40	91	8	susceptibility	susceptibility	NOUN
chd-40	91	9	of	of	ADP
chd-40	91	10	prostate	prostate	NOUN
chd-40	91	11	cancer	cancer	NOUN
chd-40	91	12	:	:	PUNCT
chd-40	91	13	a	a	DET
chd-40	91	14	meta	meta	ADJ
chd-40	91	15	-	-	PUNCT
chd-40	91	16	analysis	analysis	NOUN
chd-40	91	17	based	base	VERB
chd-40	91	18	on	on	ADP
chd-40	91	19	20	20	NUM
chd-40	91	20	publications	publication	NOUN
chd-40	91	21	.	.	PUNCT
chd-40	92	1	medicine	medicine	NOUN
chd-40	92	2	(	(	PUNCT
chd-40	92	3	baltimore	baltimore	PROPN
chd-40	92	4	)	)	PUNCT
chd-40	92	5	96	96	NUM
chd-40	92	6	,	,	PUNCT
chd-40	92	7	e6791	e6791	PROPN
chd-40	92	8	.	.	PROPN
chd-40	92	9	gaston	gaston	PROPN
chd-40	92	10	,	,	PUNCT
chd-40	92	11	k.e	k.e	PROPN
chd-40	92	12	.	.	PROPN
chd-40	92	13	,	,	PUNCT
chd-40	92	14	kim	kim	PROPN
chd-40	92	15	,	,	PUNCT
chd-40	92	16	d.	d.	PROPN
chd-40	92	17	,	,	PUNCT
chd-40	92	18	singh	singh	PROPN
chd-40	92	19	,	,	PUNCT
chd-40	92	20	s.	s.	PROPN
chd-40	92	21	,	,	PUNCT
chd-40	92	22	ford	ford	PROPN
chd-40	92	23	,	,	PUNCT
chd-40	92	24	o.h	o.h	PROPN
chd-40	92	25	.	.	PROPN
chd-40	92	26	,	,	PUNCT
chd-40	92	27	3rd	3rd	NOUN
chd-40	92	28	,	,	PUNCT
chd-40	92	29	and	and	CCONJ
chd-40	92	30	mohler	mohler	NOUN
chd-40	92	31	,	,	PUNCT
chd-40	92	32	j.l	j.l	PROPN
chd-40	92	33	.	.	PROPN
chd-40	92	34	(	(	PUNCT
chd-40	92	35	2003	2003	NUM
chd-40	92	36	)	)	PUNCT
chd-40	92	37	.	.	PUNCT
chd-40	93	1	racial	racial	ADJ
chd-40	93	2	differences	difference	NOUN
chd-40	93	3	in	in	ADP
chd-40	93	4	androgen	androgen	NOUN
chd-40	93	5	receptor	receptor	NOUN
chd-40	93	6	protein	protein	NOUN
chd-40	93	7	expression	expression	NOUN
chd-40	93	8	in	in	ADP
chd-40	93	9	men	man	NOUN
chd-40	93	10	with	with	ADP
chd-40	93	11	clinically	clinically	ADV
chd-40	93	12	localized	localize	VERB
chd-40	93	13	prostate	prostate	NOUN
chd-40	93	14	cancer	cancer	NOUN
chd-40	93	15	.	.	PUNCT
chd-40	94	1	j	j	PROPN
chd-40	94	2	urol	urol	PROPN
chd-40	94	3	170	170	NUM
chd-40	94	4	,	,	PUNCT
chd-40	94	5	990	990	NUM
chd-40	94	6	-	-	SYM
chd-40	94	7	993	993	NUM
chd-40	94	8	.	.	PUNCT
chd-40	95	1	gauthier	gauthier	NOUN
chd-40	95	2	-	-	PUNCT
chd-40	95	3	landry	landry	PROPN
chd-40	95	4	,	,	PUNCT
chd-40	95	5	l.	l.	PROPN
chd-40	95	6	,	,	PUNCT
chd-40	95	7	belanger	belanger	PROPN
chd-40	95	8	,	,	PUNCT
chd-40	95	9	a.	a.	NOUN
chd-40	95	10	,	,	PUNCT
chd-40	95	11	and	and	CCONJ
chd-40	95	12	barbier	barbier	NOUN
chd-40	95	13	,	,	PUNCT
chd-40	95	14	o.	o.	PROPN
chd-40	95	15	(	(	PUNCT
chd-40	95	16	2015	2015	NUM
chd-40	95	17	)	)	PUNCT
chd-40	95	18	.	.	PUNCT
chd-40	96	1	multiple	multiple	ADJ
chd-40	96	2	roles	role	NOUN
chd-40	96	3	for	for	ADP
chd-40	96	4	udpglucuronosyltransferase	udpglucuronosyltransferase	ADJ
chd-40	96	5	(	(	PUNCT
chd-40	96	6	ugt)2b15	ugt)2b15	X
chd-40	96	7	and	and	CCONJ
chd-40	96	8	ugt2b17	ugt2b17	ADJ
chd-40	96	9	enzymes	enzyme	NOUN
chd-40	96	10	in	in	ADP
chd-40	96	11	androgen	androgen	NOUN
chd-40	96	12	metabolism	metabolism	NOUN
chd-40	96	13	and	and	CCONJ
chd-40	96	14	prostate	prostate	NOUN
chd-40	96	15	cancer	cancer	NOUN
chd-40	96	16	evolution	evolution	NOUN
chd-40	96	17	.	.	PUNCT
chd-40	97	1	j	j	PROPN
chd-40	97	2	steroid	steroid	PROPN
chd-40	97	3	biochem	biochem	PROPN
chd-40	97	4	mol	mol	ADP
chd-40	97	5	biol	biol	PROPN
chd-40	97	6	145	145	NUM
chd-40	97	7	,	,	PUNCT
chd-40	97	8	187	187	NUM
chd-40	97	9	-	-	SYM
chd-40	97	10	192	192	NUM
chd-40	97	11	.	.	PUNCT
chd-40	98	1	gomez	gomez	PROPN
chd-40	98	2	,	,	PUNCT
chd-40	98	3	l.	l.	PROPN
chd-40	98	4	,	,	PUNCT
chd-40	98	5	kovac	kovac	PROPN
chd-40	98	6	,	,	PUNCT
chd-40	98	7	j.r	j.r	PROPN
chd-40	98	8	.	.	PROPN
chd-40	98	9	,	,	PUNCT
chd-40	98	10	and	and	CCONJ
chd-40	98	11	lamb	lamb	PROPN
chd-40	98	12	,	,	PUNCT
chd-40	98	13	d.j	d.j	PROPN
chd-40	98	14	.	.	PROPN
chd-40	98	15	(	(	PUNCT
chd-40	98	16	2015	2015	NUM
chd-40	98	17	)	)	PUNCT
chd-40	98	18	.	.	PUNCT
chd-40	99	1	cyp17a1	cyp17a1	PROPN
chd-40	99	2	inhibitors	inhibitor	NOUN
chd-40	99	3	in	in	ADP
chd-40	99	4	castration	castration	NOUN
chd-40	99	5	-	-	PUNCT
chd-40	99	6	resistant	resistant	ADJ
chd-40	99	7	prostate	prostate	NOUN
chd-40	99	8	cancer	cancer	NOUN
chd-40	99	9	.	.	PUNCT
chd-40	100	1	steroids	steroid	NOUN
chd-40	100	2	95	95	NUM
chd-40	100	3	,	,	PUNCT
chd-40	100	4	80	80	NUM
chd-40	100	5	-	-	SYM
chd-40	100	6	87	87	NUM
chd-40	100	7	.	.	PUNCT
chd-40	101	1	mitra	mitra	PROPN
chd-40	101	2	,	,	PUNCT
chd-40	101	3	r.	r.	PROPN
chd-40	101	4	,	,	PUNCT
chd-40	101	5	and	and	CCONJ
chd-40	101	6	goodman	goodman	PROPN
chd-40	101	7	,	,	PUNCT
chd-40	101	8	o.b	o.b	PROPN
chd-40	101	9	.	.	PROPN
chd-40	101	10	,	,	PUNCT
chd-40	101	11	jr	jr	PROPN
chd-40	101	12	.	.	PROPN
chd-40	101	13	(	(	PUNCT
chd-40	101	14	2015	2015	NUM
chd-40	101	15	)	)	PUNCT
chd-40	101	16	.	.	PUNCT
chd-40	102	1	cyp3a5	cyp3a5	NOUN
chd-40	102	2	regulates	regulate	VERB
chd-40	102	3	prostate	prostate	NOUN
chd-40	102	4	cancer	cancer	NOUN
chd-40	102	5	cell	cell	NOUN
chd-40	102	6	growth	growth	NOUN
chd-40	102	7	by	by	ADP
chd-40	102	8	facilitating	facilitate	VERB
chd-40	102	9	nuclear	nuclear	ADJ
chd-40	102	10	translocation	translocation	NOUN
chd-40	102	11	of	of	ADP
chd-40	102	12	ar	ar	PROPN
chd-40	102	13	.	.	PROPN
chd-40	102	14	prostate	prostate	NOUN
chd-40	102	15	75	75	NUM
chd-40	102	16	,	,	PUNCT
chd-40	102	17	527	527	NUM
chd-40	102	18	-	-	SYM
chd-40	102	19	538	538	NUM
chd-40	102	20	.	.	PUNCT
chd-40	103	1	mostaghel	mostaghel	PROPN
chd-40	103	2	,	,	PUNCT
chd-40	103	3	e.a	e.a	PROPN
chd-40	103	4	.	.	PROPN
chd-40	103	5	,	,	PUNCT
chd-40	103	6	and	and	CCONJ
chd-40	103	7	nelson	nelson	PROPN
chd-40	103	8	,	,	PUNCT
chd-40	103	9	p.s	p.s	PROPN
chd-40	103	10	.	.	PROPN
chd-40	103	11	(	(	PUNCT
chd-40	103	12	2008	2008	NUM
chd-40	103	13	)	)	PUNCT
chd-40	103	14	.	.	PUNCT
chd-40	104	1	intracrine	intracrine	VERB
chd-40	104	2	androgen	androgen	NOUN
chd-40	104	3	metabolism	metabolism	NOUN
chd-40	104	4	in	in	ADP
chd-40	104	5	prostate	prostate	NOUN
chd-40	104	6	cancer	cancer	NOUN
chd-40	104	7	progression	progression	NOUN
chd-40	104	8	:	:	PUNCT
chd-40	104	9	mechanisms	mechanism	NOUN
chd-40	104	10	of	of	ADP
chd-40	104	11	castration	castration	NOUN
chd-40	104	12	resistance	resistance	NOUN
chd-40	104	13	and	and	CCONJ
chd-40	104	14	therapeutic	therapeutic	ADJ
chd-40	104	15	implications	implication	NOUN
chd-40	104	16	.	.	PUNCT
chd-40	105	1	best	good	ADJ
chd-40	105	2	pract	pract	PROPN
chd-40	105	3	res	re	NOUN
chd-40	105	4	clin	clin	PROPN
chd-40	105	5	endocrinol	endocrinol	PROPN
chd-40	105	6	metab	metab	PROPN
chd-40	105	7	22	22	NUM
chd-40	105	8	,	,	PUNCT
chd-40	105	9	243	243	NUM
chd-40	105	10	-	-	SYM
chd-40	105	11	258	258	NUM
chd-40	105	12	.	.	PUNCT
chd-40	106	1	plata	plata	PROPN
chd-40	106	2	bello	bello	PROPN
chd-40	106	3	,	,	PUNCT
chd-40	106	4	a.	a.	NOUN
chd-40	106	5	,	,	PUNCT
chd-40	106	6	and	and	CCONJ
chd-40	106	7	concepcion	concepcion	PROPN
chd-40	106	8	masip	masip	PROPN
chd-40	106	9	,	,	PUNCT
chd-40	106	10	t.	t.	PROPN
chd-40	106	11	(	(	PUNCT
chd-40	106	12	2014	2014	NUM
chd-40	106	13	)	)	PUNCT
chd-40	106	14	.	.	PUNCT
chd-40	107	1	prostate	prostate	NOUN
chd-40	107	2	cancer	cancer	NOUN
chd-40	107	3	epidemiology	epidemiology	NOUN
chd-40	107	4	.	.	PUNCT
chd-40	108	1	arch	arch	ADJ
chd-40	108	2	esp	esp	PROPN
chd-40	108	3	urol	urol	PROPN
chd-40	108	4	67	67	NUM
chd-40	108	5	,	,	PUNCT
chd-40	108	6	373	373	NUM
chd-40	108	7	-	-	SYM
chd-40	108	8	382	382	NUM
chd-40	108	9	.	.	PUNCT
chd-40	109	1	salvi	salvi	PROPN
chd-40	109	2	,	,	PUNCT
chd-40	109	3	s.	s.	PROPN
chd-40	109	4	,	,	PUNCT
chd-40	109	5	casadio	casadio	NOUN
chd-40	109	6	,	,	PUNCT
chd-40	109	7	v.	v.	NOUN
chd-40	109	8	,	,	PUNCT
chd-40	109	9	burgio	burgio	PROPN
chd-40	109	10	,	,	PUNCT
chd-40	109	11	s.l	s.l	PROPN
chd-40	109	12	.	.	PROPN
chd-40	109	13	,	,	PUNCT
chd-40	109	14	conteduca	conteduca	PROPN
chd-40	109	15	,	,	PUNCT
chd-40	109	16	v.	v.	PROPN
chd-40	109	17	,	,	PUNCT
chd-40	109	18	rossi	rossi	ADJ
chd-40	109	19	,	,	PUNCT
chd-40	109	20	l.	l.	PROPN
chd-40	109	21	,	,	PUNCT
chd-40	109	22	menna	menna	PROPN
chd-40	109	23	,	,	PUNCT
chd-40	109	24	c.	c.	PROPN
chd-40	109	25	,	,	PUNCT
chd-40	109	26	carretta	carretta	PROPN
chd-40	109	27	,	,	PUNCT
chd-40	109	28	e.	e.	PROPN
chd-40	109	29	,	,	PUNCT
chd-40	109	30	costantini	costantini	PROPN
chd-40	109	31	,	,	PUNCT
chd-40	109	32	m.	m.	NOUN
chd-40	109	33	,	,	PUNCT
chd-40	109	34	zoli	zoli	PROPN
chd-40	109	35	,	,	PUNCT
chd-40	109	36	w.	w.	PROPN
chd-40	109	37	,	,	PUNCT
chd-40	109	38	and	and	CCONJ
chd-40	109	39	de	de	ADP
chd-40	109	40	giorgi	giorgi	PROPN
chd-40	109	41	,	,	PUNCT
chd-40	109	42	u.	u.	PROPN
chd-40	109	43	(	(	PUNCT
chd-40	109	44	2016	2016	NUM
chd-40	109	45	)	)	PUNCT
chd-40	109	46	.	.	PUNCT
chd-40	110	1	cyp17a1	cyp17a1	PROPN
chd-40	110	2	polymorphisms	polymorphism	NOUN
chd-40	110	3	and	and	CCONJ
chd-40	110	4	clinical	clinical	ADJ
chd-40	110	5	outcome	outcome	NOUN
chd-40	110	6	of	of	ADP
chd-40	110	7	castration	castration	NOUN
chd-40	110	8	-	-	PUNCT
chd-40	110	9	resistant	resistant	ADJ
chd-40	110	10	prostate	prostate	NOUN
chd-40	110	11	cancer	cancer	NOUN
chd-40	110	12	patients	patient	NOUN
chd-40	110	13	treated	treat	VERB
chd-40	110	14	with	with	ADP
chd-40	110	15	abiraterone	abiraterone	NOUN
chd-40	110	16	.	.	PUNCT
chd-40	111	1	int	int	PROPN
chd-40	111	2	j	j	PROPN
chd-40	111	3	biol	biol	PROPN
chd-40	111	4	markers	marker	NOUN
chd-40	111	5	31	31	NUM
chd-40	111	6	,	,	PUNCT
chd-40	111	7	e264	e264	PROPN
chd-40	111	8	-	-	SYM
chd-40	111	9	269	269	NUM
chd-40	111	10	.	.	PUNCT
chd-40	112	1	schaid	schaid	PROPN
chd-40	112	2	,	,	PUNCT
chd-40	112	3	d.j	d.j	PROPN
chd-40	112	4	.	.	PROPN
chd-40	112	5	(	(	PUNCT
chd-40	112	6	2004	2004	NUM
chd-40	112	7	)	)	PUNCT
chd-40	112	8	.	.	PUNCT
chd-40	113	1	the	the	DET
chd-40	113	2	complex	complex	ADJ
chd-40	113	3	genetic	genetic	ADJ
chd-40	113	4	epidemiology	epidemiology	NOUN
chd-40	113	5	of	of	ADP
chd-40	113	6	prostate	prostate	NOUN
chd-40	113	7	cancer	cancer	NOUN
chd-40	113	8	.	.	PUNCT
chd-40	114	1	hum	hum	PROPN
chd-40	114	2	mol	mol	ADP
chd-40	114	3	genet	genet	PROPN
chd-40	114	4	13	13	NUM
chd-40	114	5	spec	spec	NOUN
chd-40	114	6	no	no	DET
chd-40	114	7	1	1	NUM
chd-40	114	8	,	,	PUNCT
chd-40	114	9	r103	r103	PROPN
chd-40	114	10	-	-	SYM
chd-40	114	11	121	121	NUM
chd-40	114	12	.	.	PUNCT
chd-40	115	1	siegel	siegel	PROPN
chd-40	115	2	,	,	PUNCT
chd-40	115	3	r.l	r.l	PROPN
chd-40	115	4	.	.	PROPN
chd-40	115	5	,	,	PUNCT
chd-40	115	6	miller	miller	PROPN
chd-40	115	7	,	,	PUNCT
chd-40	115	8	k.d	k.d	PROPN
chd-40	115	9	.	.	PROPN
chd-40	115	10	,	,	PUNCT
chd-40	115	11	and	and	CCONJ
chd-40	115	12	jemal	jemal	ADJ
chd-40	115	13	,	,	PUNCT
chd-40	115	14	a.	a.	NOUN
chd-40	115	15	(	(	PUNCT
chd-40	115	16	2017	2017	NUM
chd-40	115	17	)	)	PUNCT
chd-40	115	18	.	.	PUNCT
chd-40	116	1	cancer	cancer	NOUN
chd-40	116	2	statistics	statistic	NOUN
chd-40	116	3	,	,	PUNCT
chd-40	116	4	2017	2017	NUM
chd-40	116	5	.	.	PUNCT
chd-40	117	1	ca	can	AUX
chd-40	117	2	cancer	cancer	PROPN
chd-40	117	3	j	j	PROPN
chd-40	117	4	clin	clin	PROPN
chd-40	117	5	67	67	NUM
chd-40	117	6	,	,	PUNCT
chd-40	117	7	730	730	NUM
chd-40	117	8	.	.	PUNCT
chd-40	117	9	          	          	SPACE
chd-40	117	10	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-40	117	11	e6	e6	VERB
chd-40	117	12	cancer	cancer	NOUN
chd-40	117	13	health	health	NOUN
chd-40	117	14	disparities	disparity	NOUN
chd-40	117	15	  	  	SPACE
chd-40	117	16	research	research	NOUN
chd-40	117	17	simard	simard	PROPN
chd-40	117	18	,	,	PUNCT
chd-40	117	19	j.	j.	PROPN
chd-40	117	20	,	,	PUNCT
chd-40	117	21	durocher	durocher	PROPN
chd-40	117	22	,	,	PUNCT
chd-40	117	23	f.	f.	PROPN
chd-40	117	24	,	,	PUNCT
chd-40	117	25	mebarki	mebarki	PROPN
chd-40	117	26	,	,	PUNCT
chd-40	117	27	f.	f.	PROPN
chd-40	117	28	,	,	PUNCT
chd-40	117	29	turgeon	turgeon	PROPN
chd-40	117	30	,	,	PUNCT
chd-40	117	31	c.	c.	PROPN
chd-40	117	32	,	,	PUNCT
chd-40	117	33	sanchez	sanchez	PROPN
chd-40	117	34	,	,	PUNCT
chd-40	117	35	r.	r.	PROPN
chd-40	117	36	,	,	PUNCT
chd-40	117	37	labrie	labrie	PROPN
chd-40	117	38	,	,	PUNCT
chd-40	117	39	y.	y.	PROPN
chd-40	117	40	,	,	PUNCT
chd-40	117	41	couet	couet	PROPN
chd-40	117	42	,	,	PUNCT
chd-40	117	43	j.	j.	PROPN
chd-40	117	44	,	,	PUNCT
chd-40	117	45	trudel	trudel	PROPN
chd-40	117	46	,	,	PUNCT
chd-40	117	47	c.	c.	NOUN
chd-40	117	48	,	,	PUNCT
chd-40	117	49	rheaume	rheaume	NOUN
chd-40	117	50	,	,	PUNCT
chd-40	117	51	e.	e.	PROPN
chd-40	117	52	,	,	PUNCT
chd-40	117	53	morel	morel	PROPN
chd-40	117	54	,	,	PUNCT
chd-40	117	55	y.	y.	PROPN
chd-40	117	56	,	,	PUNCT
chd-40	117	57	et	et	PROPN
chd-40	117	58	al	al	PROPN
chd-40	117	59	.	.	PUNCT
chd-40	118	1	(	(	PUNCT
chd-40	118	2	1996	1996	NUM
chd-40	118	3	)	)	PUNCT
chd-40	118	4	.	.	PUNCT
chd-40	119	1	molecular	molecular	ADJ
chd-40	119	2	biology	biology	NOUN
chd-40	119	3	and	and	CCONJ
chd-40	119	4	genetics	genetic	NOUN
chd-40	119	5	of	of	ADP
chd-40	119	6	the	the	DET
chd-40	119	7	3	3	NUM
chd-40	119	8	betahydroxysteroid	betahydroxysteroid	NOUN
chd-40	119	9	dehydrogenase	dehydrogenase	NOUN
chd-40	119	10	/	/	SYM
chd-40	119	11	delta5	delta5	NOUN
chd-40	119	12	-	-	PUNCT
chd-40	119	13	delta4	delta4	NOUN
chd-40	119	14	isomerase	isomerase	ADJ
chd-40	119	15	gene	gene	NOUN
chd-40	119	16	family	family	NOUN
chd-40	119	17	.	.	PUNCT
chd-40	120	1	j	j	PROPN
chd-40	120	2	endocrinol	endocrinol	NOUN
chd-40	120	3	150	150	NUM
chd-40	120	4	suppl	suppl	ADJ
chd-40	120	5	,	,	PUNCT
chd-40	120	6	s189	s189	PROPN
chd-40	120	7	-	-	PUNCT
chd-40	120	8	207	207	NUM
chd-40	120	9	.	.	PUNCT
chd-40	121	1	singh	singh	PROPN
chd-40	121	2	,	,	PUNCT
chd-40	121	3	s.k	s.k	PROPN
chd-40	121	4	.	.	PROPN
chd-40	121	5	,	,	PUNCT
chd-40	121	6	lillard	lillard	PROPN
chd-40	121	7	,	,	PUNCT
chd-40	121	8	j.w	j.w	PROPN
chd-40	121	9	.	.	PROPN
chd-40	121	10	,	,	PUNCT
chd-40	121	11	jr	jr	PROPN
chd-40	121	12	.	.	PROPN
chd-40	121	13	,	,	PUNCT
chd-40	121	14	and	and	CCONJ
chd-40	121	15	singh	singh	PROPN
chd-40	121	16	,	,	PUNCT
chd-40	121	17	r.	r.	PROPN
chd-40	121	18	(	(	PUNCT
chd-40	121	19	2017	2017	NUM
chd-40	121	20	)	)	PUNCT
chd-40	121	21	.	.	PUNCT
chd-40	122	1	molecular	molecular	ADJ
chd-40	122	2	basis	basis	NOUN
chd-40	122	3	for	for	ADP
chd-40	122	4	prostate	prostate	NOUN
chd-40	122	5	cancer	cancer	NOUN
chd-40	122	6	racial	racial	ADJ
chd-40	122	7	disparities	disparity	NOUN
chd-40	122	8	.	.	PUNCT
chd-40	123	1	front	front	ADJ
chd-40	123	2	biosci	biosci	PROPN
chd-40	123	3	(	(	PUNCT
chd-40	123	4	landmark	landmark	PROPN
chd-40	123	5	ed	ed	NOUN
chd-40	123	6	)	)	PUNCT
chd-40	123	7	22	22	NUM
chd-40	123	8	,	,	PUNCT
chd-40	123	9	428450	428450	NUM
chd-40	123	10	.	.	PUNCT
chd-40	124	1	welsh	welsh	PROPN
chd-40	124	2	,	,	PUNCT
chd-40	124	3	j.s	j.s	PROPN
chd-40	124	4	.	.	PROPN
chd-40	124	5	,	,	PUNCT
chd-40	124	6	and	and	CCONJ
chd-40	124	7	hentz	hentz	ADJ
chd-40	124	8	,	,	PUNCT
chd-40	124	9	c.	c.	PROPN
chd-40	124	10	(	(	PUNCT
chd-40	124	11	2017	2017	NUM
chd-40	124	12	)	)	PUNCT
chd-40	124	13	.	.	PUNCT
chd-40	125	1	androgen	androgen	NOUN
chd-40	125	2	deprivation	deprivation	NOUN
chd-40	125	3	therapy	therapy	NOUN
chd-40	125	4	and	and	CCONJ
chd-40	125	5	subsequent	subsequent	ADJ
chd-40	125	6	dementia	dementia	NOUN
chd-40	125	7	.	.	PUNCT
chd-40	126	1	jama	jama	PROPN
chd-40	126	2	oncol	oncol	PROPN
chd-40	126	3	3	3	NUM
chd-40	126	4	,	,	PUNCT
chd-40	126	5	1000	1000	NUM
chd-40	126	6	-	-	SYM
chd-40	126	7	1001	1001	NUM
chd-40	126	8	.	.	PUNCT
chd-40	127	1	yang	yang	PROPN
chd-40	127	2	,	,	PUNCT
chd-40	127	3	d.d	d.d	PROPN
chd-40	127	4	.	.	PROPN
chd-40	127	5	,	,	PUNCT
chd-40	127	6	muralidhar	muralidhar	PROPN
chd-40	127	7	,	,	PUNCT
chd-40	127	8	v.	v.	PROPN
chd-40	127	9	,	,	PUNCT
chd-40	127	10	mahal	mahal	PROPN
chd-40	127	11	,	,	PUNCT
chd-40	127	12	b.a	b.a	PROPN
chd-40	127	13	.	.	PROPN
chd-40	127	14	,	,	PUNCT
chd-40	127	15	nezolosky	nezolosky	PROPN
chd-40	127	16	,	,	PUNCT
chd-40	127	17	m.d	m.d	PROPN
chd-40	127	18	.	.	PROPN
chd-40	127	19	,	,	PUNCT
chd-40	127	20	labe	labe	PROPN
chd-40	127	21	,	,	PUNCT
chd-40	127	22	s.a	s.a	PROPN
chd-40	127	23	.	.	PROPN
chd-40	127	24	,	,	PUNCT
chd-40	127	25	vastola	vastola	PROPN
chd-40	127	26	,	,	PUNCT
chd-40	127	27	m.e	m.e	PROPN
chd-40	127	28	.	.	PROPN
chd-40	127	29	,	,	PUNCT
chd-40	127	30	boldbaatar	boldbaatar	PROPN
chd-40	127	31	,	,	PUNCT
chd-40	127	32	n.	n.	NOUN
chd-40	127	33	,	,	PUNCT
chd-40	127	34	king	king	NOUN
chd-40	127	35	,	,	PUNCT
chd-40	127	36	m.t	m.t	PROPN
chd-40	127	37	.	.	PROPN
chd-40	127	38	,	,	PUNCT
chd-40	127	39	martin	martin	PROPN
chd-40	127	40	,	,	PUNCT
chd-40	127	41	n.e	n.e	PROPN
chd-40	127	42	.	.	PROPN
chd-40	127	43	,	,	PUNCT
chd-40	127	44	orio	orio	PROPN
chd-40	127	45	,	,	PUNCT
chd-40	127	46	p.f	p.f	PROPN
chd-40	127	47	.	.	PROPN
chd-40	127	48	,	,	PUNCT
chd-40	127	49	3rd	3rd	NOUN
chd-40	127	50	,	,	PUNCT
chd-40	127	51	et	et	PROPN
chd-40	127	52	al	al	PROPN
chd-40	127	53	.	.	PUNCT
chd-40	127	54	(	(	PUNCT
chd-40	127	55	2017	2017	NUM
chd-40	127	56	)	)	PUNCT
chd-40	127	57	.	.	PUNCT
chd-40	128	1	low	low	ADJ
chd-40	128	2	rates	rate	NOUN
chd-40	128	3	of	of	ADP
chd-40	128	4	androgen	androgen	NOUN
chd-40	128	5	deprivation	deprivation	NOUN
chd-40	128	6	therapy	therapy	NOUN
chd-40	128	7	use	use	NOUN
chd-40	128	8	with	with	ADP
chd-40	128	9	salvage	salvage	NOUN
chd-40	128	10	radiation	radiation	NOUN
chd-40	128	11	therapy	therapy	NOUN
chd-40	128	12	in	in	ADP
chd-40	128	13	patients	patient	NOUN
chd-40	128	14	with	with	ADP
chd-40	128	15	prostate	prostate	NOUN
chd-40	128	16	cancer	cancer	NOUN
chd-40	128	17	after	after	ADP
chd-40	128	18	radical	radical	ADJ
chd-40	128	19	prostatectomy	prostatectomy	NOUN
chd-40	128	20	.	.	PUNCT
chd-40	129	1	urol	urol	ADJ
chd-40	129	2	oncol	oncol	ADJ
chd-40	129	3	35	35	NUM
chd-40	129	4	,	,	PUNCT
chd-40	129	5	542	542	NUM
chd-40	129	6	e525	e525	PROPN
chd-40	129	7	-	-	PUNCT
chd-40	129	8	542	542	NUM
chd-40	129	9	e532	e532	PROPN
chd-40	129	10	.	.	PROPN
chd-40	129	11	yepuru	yepuru	PROPN
chd-40	129	12	,	,	PUNCT
chd-40	129	13	m.	m.	NOUN
chd-40	129	14	,	,	PUNCT
chd-40	129	15	wu	wu	PROPN
chd-40	129	16	,	,	PUNCT
chd-40	129	17	z.	z.	PROPN
chd-40	129	18	,	,	PUNCT
chd-40	129	19	kulkarni	kulkarni	PROPN
chd-40	129	20	,	,	PUNCT
chd-40	129	21	a.	a.	PROPN
chd-40	129	22	,	,	PUNCT
chd-40	129	23	yin	yin	PROPN
chd-40	129	24	,	,	PUNCT
chd-40	129	25	f.	f.	PROPN
chd-40	129	26	,	,	PUNCT
chd-40	129	27	barrett	barrett	PROPN
chd-40	129	28	,	,	PUNCT
chd-40	129	29	c.m	c.m	PROPN
chd-40	129	30	.	.	PROPN
chd-40	129	31	,	,	PUNCT
chd-40	129	32	kim	kim	PROPN
chd-40	129	33	,	,	PUNCT
chd-40	129	34	j.	j.	PROPN
chd-40	129	35	,	,	PUNCT
chd-40	129	36	steiner	steiner	PROPN
chd-40	129	37	,	,	PUNCT
chd-40	129	38	m.s	m.s	PROPN
chd-40	129	39	.	.	PROPN
chd-40	129	40	,	,	PUNCT
chd-40	129	41	miller	miller	PROPN
chd-40	129	42	,	,	PUNCT
chd-40	129	43	d.d	d.d	PROPN
chd-40	129	44	.	.	PROPN
chd-40	129	45	,	,	PUNCT
chd-40	129	46	dalton	dalton	PROPN
chd-40	129	47	,	,	PUNCT
chd-40	129	48	j.t	j.t	PROPN
chd-40	129	49	.	.	PROPN
chd-40	129	50	,	,	PUNCT
chd-40	129	51	and	and	CCONJ
chd-40	129	52	narayanan	narayanan	PROPN
chd-40	129	53	,	,	PUNCT
chd-40	129	54	r.	r.	PROPN
chd-40	129	55	(	(	PUNCT
chd-40	129	56	2013	2013	NUM
chd-40	129	57	)	)	PUNCT
chd-40	129	58	.	.	PUNCT
chd-40	130	1	steroidogenic	steroidogenic	ADJ
chd-40	130	2	enzyme	enzyme	NOUN
chd-40	130	3	akr1c3	akr1c3	NOUN
chd-40	130	4	is	be	AUX
chd-40	130	5	a	a	DET
chd-40	130	6	novel	novel	ADJ
chd-40	130	7	androgen	androgen	NOUN
chd-40	130	8	receptorselective	receptorselective	ADJ
chd-40	130	9	coactivator	coactivator	NOUN
chd-40	130	10	that	that	PRON
chd-40	130	11	promotes	promote	VERB
chd-40	130	12	prostate	prostate	NOUN
chd-40	130	13	cancer	cancer	NOUN
chd-40	130	14	growth	growth	NOUN
chd-40	130	15	.	.	PUNCT
chd-40	131	1	clin	clin	PROPN
chd-40	131	2	cancer	cancer	NOUN
chd-40	131	3	res	re	VERB
chd-40	131	4	19	19	NUM
chd-40	131	5	,	,	PUNCT
chd-40	131	6	5613	5613	NUM
chd-40	131	7	-	-	SYM
chd-40	131	8	5625	5625	NUM
chd-40	131	9	.	.	PUNCT
chd-40	132	1	young	young	ADJ
chd-40	132	2	,	,	PUNCT
chd-40	132	3	j.w.s	j.w.s	INTJ
chd-40	132	4	.	.	PUNCT
chd-40	132	5	,	,	PUNCT
chd-40	132	6	sutradhar	sutradhar	PROPN
chd-40	132	7	,	,	PUNCT
chd-40	132	8	r.	r.	PROPN
chd-40	132	9	,	,	PUNCT
chd-40	132	10	rangrej	rangrej	PROPN
chd-40	132	11	,	,	PUNCT
chd-40	132	12	j.	j.	PROPN
chd-40	132	13	,	,	PUNCT
chd-40	132	14	marras	marras	PROPN
chd-40	132	15	,	,	PUNCT
chd-40	132	16	c.	c.	NOUN
chd-40	132	17	,	,	PUNCT
chd-40	132	18	fleshner	fleshner	NOUN
chd-40	132	19	,	,	PUNCT
chd-40	132	20	n.	n.	NOUN
chd-40	132	21	,	,	PUNCT
chd-40	132	22	and	and	CCONJ
chd-40	132	23	alibhai	alibhai	ADJ
chd-40	132	24	,	,	PUNCT
chd-40	132	25	s.m.h	s.m.h	ADJ
chd-40	132	26	.	.	PUNCT
chd-40	133	1	(	(	PUNCT
chd-40	133	2	2017	2017	NUM
chd-40	133	3	)	)	PUNCT
chd-40	133	4	.	.	PUNCT
chd-40	134	1	androgen	androgen	NOUN
chd-40	134	2	deprivation	deprivation	NOUN
chd-40	134	3	therapy	therapy	NOUN
chd-40	134	4	and	and	CCONJ
chd-40	134	5	the	the	DET
chd-40	134	6	risk	risk	NOUN
chd-40	134	7	of	of	ADP
chd-40	134	8	parkinsonism	parkinsonism	NOUN
chd-40	134	9	in	in	ADP
chd-40	134	10	men	man	NOUN
chd-40	134	11	with	with	ADP
chd-40	134	12	prostate	prostate	NOUN
chd-40	134	13	cancer	cancer	NOUN
chd-40	134	14	.	.	PUNCT
chd-40	135	1	world	world	PROPN
chd-40	135	2	j	j	PROPN
chd-40	135	3	urol	urol	PROPN
chd-40	135	4	35	35	NUM
chd-40	135	5	,	,	PUNCT
chd-40	135	6	1417	1417	NUM
chd-40	135	7	-	-	SYM
chd-40	135	8	1423	1423	NUM
chd-40	135	9	.	.	PUNCT
chd-40	136	1	zeigler	zeigler	PROPN
chd-40	136	2	-	-	PUNCT
chd-40	136	3	johnson	johnson	PROPN
chd-40	136	4	,	,	PUNCT
chd-40	136	5	c.	c.	PROPN
chd-40	136	6	,	,	PUNCT
chd-40	136	7	morales	morale	NOUN
chd-40	136	8	,	,	PUNCT
chd-40	136	9	k.h	k.h	PROPN
chd-40	136	10	.	.	PROPN
chd-40	136	11	,	,	PUNCT
chd-40	136	12	spangler	spangler	PROPN
chd-40	136	13	,	,	PUNCT
chd-40	136	14	e.	e.	PROPN
chd-40	136	15	,	,	PUNCT
chd-40	136	16	chang	chang	PROPN
chd-40	136	17	,	,	PUNCT
chd-40	136	18	b.l	b.l	PROPN
chd-40	136	19	.	.	PROPN
chd-40	136	20	,	,	PUNCT
chd-40	136	21	and	and	CCONJ
chd-40	136	22	rebbeck	rebbeck	NOUN
chd-40	136	23	,	,	PUNCT
chd-40	136	24	t.r	t.r	PROPN
chd-40	136	25	.	.	PROPN
chd-40	136	26	(	(	PUNCT
chd-40	136	27	2013	2013	NUM
chd-40	136	28	)	)	PUNCT
chd-40	136	29	.	.	PUNCT
chd-40	137	1	relationship	relationship	NOUN
chd-40	137	2	of	of	ADP
chd-40	137	3	early	early	ADJ
chd-40	137	4	-	-	PUNCT
chd-40	137	5	onset	onset	NOUN
chd-40	137	6	baldness	baldness	NOUN
chd-40	137	7	to	to	ADP
chd-40	137	8	prostate	prostate	NOUN
chd-40	137	9	cancer	cancer	NOUN
chd-40	137	10	in	in	ADP
chd-40	137	11	african	african	ADJ
chd-40	137	12	-	-	PUNCT
chd-40	137	13	american	american	ADJ
chd-40	137	14	men	man	NOUN
chd-40	137	15	.	.	PUNCT
chd-40	138	1	cancer	cancer	NOUN
chd-40	138	2	epidemiol	epidemiol	PROPN
chd-40	138	3	biomarkers	biomarkers	PROPN
chd-40	138	4	prev	prev	VERB
chd-40	138	5	22	22	NUM
chd-40	138	6	,	,	PUNCT
chd-40	138	7	589596	589596	NUM
chd-40	138	8	.	.	PUNCT